TW200927740A - Process - Google Patents

Process Download PDF

Info

Publication number
TW200927740A
TW200927740A TW097143774A TW97143774A TW200927740A TW 200927740 A TW200927740 A TW 200927740A TW 097143774 A TW097143774 A TW 097143774A TW 97143774 A TW97143774 A TW 97143774A TW 200927740 A TW200927740 A TW 200927740A
Authority
TW
Taiwan
Prior art keywords
compound
formula
thione
aminoethyl
group
Prior art date
Application number
TW097143774A
Other languages
Chinese (zh)
Inventor
Alexander Beliaev
David Alexander Learmonth
Brian Broadbelt
Original Assignee
Bial Portela & Ca Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bial Portela & Ca Sa filed Critical Bial Portela & Ca Sa
Publication of TW200927740A publication Critical patent/TW200927740A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Abstract

Compounds of formula I, V, VI and II, and processes for their preparation, wherein R1, R2 and R3 are the same or different and signify hydrogens, halogens, alkyl, alkyloxy, hydroxy, nitro, alkylcarbonylamino, alkylamino or dialkylamino group; and R4 is alkyl or aryl. There is also provided a process for preparing a compound of formula B from the compounds of formula V and I.

Description

200927740 九、發明說明: 【發明所屬之技術領域】 本發明係關於製備適用於合成多巴胺-β-羥化酶之周邊 選擇性(peripherally-selective)抑制劑之中間體的改良方法 及新穎中間體。 【先前技術】 (R)-5-(2-胺基乙基)-1-(6,8-二氟'7克〇完-3-基)-1,3-二氫11米 唑-2-硫酮鹽酸鹽(下文之式P化合物)為ϋβΗ之有效、無毒 © 且具周邊選擇性之抑制劑,其可用於治療某些心血管病 症。化合物Ρ連同其製備方法係揭示於WO 2004/033447 中 〇200927740 IX. INSTRUCTIONS OF THE INVENTION: TECHNICAL FIELD OF THE INVENTION The present invention relates to an improved process and novel intermediate for the preparation of intermediates suitable for the synthesis of peripherally-selective inhibitors of dopamine-β-hydroxylase. [Prior Art] (R)-5-(2-Aminoethyl)-1-(6,8-difluoro '7 g of hydrazin-3-yl)-1,3-dihydro 11-mazole-2 -thione hydrochloride (compound of formula P below) is an effective, non-toxic, and peripherally selective inhibitor of ϋβΗ, which is useful in the treatment of certain cardiovascular conditions. The compound oxime together with its preparation method is disclosed in WO 2004/033447 〇

❹ 於W〇 2004/033447中揭示之方法包括(R)_6,8_二氟咣咬_ 3-基胺鹽酸鹽((R)-6,8-二氟吭咣-3-基胺之結構如以下化合 物Q所示)、[4_(第三丁基二甲基矽烷基氧基)_3_側氧基丁 基]胺基甲酸第三丁酯及硫氰酸鉀之反應。The method disclosed in W〇2004/033447 includes (R)-6,8-difluoroguanidine-3-ylamine hydrochloride ((R)-6,8-difluoroindol-3-ylamine The structure is as shown in the following compound Q), [4_(t-butyldimethylsilylalkyloxy)_3_sideoxybutyl]aminocarboxylic acid tert-butyl ester and potassium thiocyanate.

NH2NH2

Q (R)-6,8-二氟咣啶-3-基胺(化合物Q)為合成化合物p中之 135964.doc 200927740 關鍵中間體。在胺所連接之碳原子上的立體化學使化合物 P產生立體化學’因此化合物Q儘可能呈純形式較為有利。 換言之’應以化合物(^之R對映異構體為主,而存在少許 或不存在S對映異構體。 【發明内容】 現已發現製備適用於合成化合物P之中間體之有利方 法。中間體為具有式B之化合物。Q(R)-6,8-difluoroacridin-3-ylamine (Compound Q) is a key intermediate in the synthesis of compound 135964.doc 200927740. The stereochemistry at the carbon atom to which the amine is attached gives compound P a stereochemistry' so it is advantageous for compound Q to be as pure as possible. In other words, 'the R enantiomer of the compound should be predominant, with little or no S enantiomer. [Explanation] It has now been found to be advantageous to prepare an intermediate suitable for the synthesis of compound P. The intermediate is a compound of formula B.

該等有利方法包括將式VII化合物Such advantageous methods include the compound of formula VII

轉化成式B化合物’其中尺4為烷基或芳基且&為%或 -NH2。 一種方法包括將羧基疊氮化物(亦即心為_n3之式VII化合 物)轉化成式B化合物。羧基疊氮化物可由相應羧酸製備。 相應缓酸可由相應腈製備。相應腈之前驅體可由相應酚化 合物製備。 另一方法包括將酿胺(亦即尺5為_耶2之式VII化合物)轉化 成式B化合物。醯胺可由相應腈製備。腈可由相應醛製 備。醛之前驅體可由相應酚化合物生成。 因此’在最廣泛之態樣中,本發明提供製備式B化合物 135964.doc 200927740 之方法,其包含將式VII化合物轉化成式B化合物 r2 lx/ R«Conversion to a compound of formula B wherein the rule 4 is an alkyl or aryl group and & is % or -NH2. One method involves the conversion of a carboxy azide (i.e., a compound of formula VII having a core of _n3) to a compound of formula B. The carboxy azide can be prepared from the corresponding carboxylic acid. The corresponding slow acid can be prepared from the corresponding nitrile. The corresponding nitrile precursor can be prepared from the corresponding phenolic compound. Another method involves the conversion of a brewing amine (i.e., a compound of formula VII of size 5 to y-2) to a compound of formula B. The guanamine can be prepared from the corresponding nitrile. The nitrile can be prepared from the corresponding aldehyde. The aldehyde precursor can be formed from the corresponding phenolic compound. Thus, in the broadest aspect, the invention provides a process for the preparation of a compound of formula B 135964.doc 200927740 which comprises converting a compound of formula VII to a compound of formula B r2 lx/ R«

VII r3 0 Β ❹ ❹ 其中Ri、R2及R3為相同或不同且表示氫、鹵素、院基、烧 基氧基、羥基、硝基、烷基羰基胺基、烷基胺基或二烷基 胺基;R4為烷基或芳基;且R5為-N3或-NH2,其中:術語 烷基意謂直鏈或支鏈、含有一至六個碳原子、視情況經芳 基、烷氧基、函素、烷氧羰基或羥基羰基取代之烴鏈;術 語芳基意謂視情況經烷基氧基、函素或硝基取代之苯基或 秦基,且術語_素意謂氣、氯、漠或蛾。在·一實施例中, Rs為-Ν3。或者R5為·Νη2。該轉化法適當地包含重排反 應.。當R·5為-Ν3時,重組反應可包含庫爾提斯(Curtius)重組 反應。當R5為-NH2時,重組反應可包含霍夫曼(Hoffman) 重組反應。 【實施方式】 根據本發明之一態樣,提供製備式B化合物之方法,VII r3 0 Β ❹ ❹ wherein Ri, R 2 and R 3 are the same or different and represent hydrogen, halogen, aryl, alkyloxy, hydroxy, nitro, alkylcarbonylamino, alkylamino or dialkylamine R4 is alkyl or aryl; and R5 is -N3 or -NH2, wherein: the term alkyl means straight or branched, containing from one to six carbon atoms, optionally aryl, alkoxy, or a hydrocarbon chain substituted with a hydrazine, an alkoxycarbonyl group or a hydroxycarbonyl group; the term aryl means a phenyl or a phenyl group substituted by an alkyloxy group, a aryl group or a nitro group, and the term _ 素 means gas, chlorine, desert Or moth. In an embodiment, Rs is -Ν3. Or R5 is ·Νη2. The conversion method suitably includes a rearrangement reaction. When R·5 is -Ν3, the recombination reaction may comprise a Curtius recombination reaction. When R5 is -NH2, the recombination reaction may comprise a Hoffman recombination reaction. [Embodiment] According to one aspect of the present invention, there is provided a method of preparing a compound of Formula B,

該方法包含將式I化合物The method comprises the compound of formula I

轉化成式B化合物,其中Ri、心及!^為相同或不同且表示 135964.doc -9- 200927740 氫、鹵素、烷基、烷基氧基、羥基、硝基、烷基羰基胺 基、烧基胺基或二烷基胺基;且尺4為烷基或芳基,其中: 術語烷基意謂直鏈或支鏈、含有一至六個碳原子、視情況 經芳基、烷氧基、鹵素、烷氧羰基或羥基羰基取代之烴 鏈,術S吾芳基意謂視情況經烷基氧基、齒素或硝基取代之 苯基或萘基;且術語鹵素意謂氟、氣、溴或碘。Converted to a compound of formula B, where Ri, heart and! ^ is the same or different and represents 135964.doc -9- 200927740 hydrogen, halogen, alkyl, alkyloxy, hydroxy, nitro, alkylcarbonylamino, alkylamino or dialkylamine; 4 is an alkyl group or an aryl group, wherein: the term alkyl means a straight or branched hydrocarbon chain having one to six carbon atoms, optionally substituted by an aryl group, an alkoxy group, a halogen, an alkoxycarbonyl group or a hydroxycarbonyl group. By S, aryl refers to a phenyl or naphthyl group optionally substituted with an alkyloxy group, a dentate or a nitro group; and the term halogen means fluorine, gas, bromine or iodine.

在一實施例中,Rl、R2及K·3之至少一者為氟。在另一實 施例中,化合物I具有下式J AIn one embodiment, at least one of R1, R2, and K·3 is fluorine. In another embodiment, Compound I has the formula J A

在實施例中,R4為Cl至c4燒基。R4視情況為曱基、乙 基或第三丁基。R4較佳為甲基。纟另-實施例中,R4為苄 基。 在一實施例中 ❹ 該方法如下所示。In an embodiment, R4 is a Cl to C4 alkyl group. R4 is optionally a thiol group, an ethyl group or a tert-butyl group. R4 is preferably a methyl group. In another embodiment, R4 is benzyl. In an embodiment ❹ the method is as follows.

I形成B之轉化可包合 匕舍貫現醯胺之重組反應以形成胺基甲 酸醋’例如霍夫f .p 又菫、,且反應。該重組反應可在次氣酸鹽及 式R4〇H之醇存在 (其中尺4具有如上文所給出之相同意義:The conversion of I to form B can encompass the recombination reaction of decylamine to form a urethane acetonate such as Hoff. The recombination reaction can be carried out in the sub-acid salt and the alcohol of the formula R4〇H (wherein the rule 4 has the same meaning as given above:

灯。R·4適當地為甲Ilight. R·4 is appropriately A I

基。。人氣酸鹽通常為次氣酸之鹼金屬 鹽,例如次氯酸鈉。哈·A A 示久氣酸鹽之外的次鹵酸鹽,例如次 135964.doc 200927740 溴酸鹽,亦可用於該重組反應中。j形成6之轉化適當地包 含在次氣酸納及甲醇存在下之重組反應。 在一實施例中,可將化合物〗及醇R4〇H在約1(rc以下, 最佳為5。(:以下之溫度下攪拌,隨之將鹼金屬次氣酸鹽(通 常次氯酸鈉)之水溶液以維持内部溫度低於1〇。〇之速率裝 入。接著可將反應物在5°C下攪拌一段時間,通常3〇分 鐘。接著藉由添加鹼(諸如鹼金屬氫氧化物,通常氫氧化 納)溶液(以維持内部溫度低於約1G°C之速率裝人反應物中) 使包含N·氣醯胺中間體之反應物驗化。接著可將反應物溫 度維持在低於1(rc一段時間,通常約3〇分鐘,隨後將反應 物溫度調節至約2(TC至約3(rc範圍内,通常2rc之溫度。 接著可將此溫度維持約15小時至約30小時範圍内,通常約 20小時至約25小時之時間,隨之接著將反應物調節至低於 l〇°C,通常約5°C之溫度,隨後裝入諸如鹽酸之酸,且維 持所得懸浮液之溫度在約,歷時至少㈠、時。接著可過 # 濾產物且以含水甲醇(通常1:1,KOiMeOH)洗滌並真空乾 燥,得到呈白色微晶固體之化合物B ^ 例如可藉由再結晶來純化B形成!之轉化產物。可在水與 2_丙醇之混合物存在下實現再結晶。 根據本發明之另-態樣,提供製傷如上所定義式j化合 物之方法。該方法包括將式π化合物 轉化成式1化合物,其中R丨、R2及I具有如上文所給出之 135964.doc 200927740 相同意義。base. . The popular acid salt is usually an alkali metal salt of a sub-acid, such as sodium hypochlorite. Ha·A A shows a hypohalite other than the long-acid acid salt, for example, 135964.doc 200927740 bromate, which can also be used in the recombination reaction. The conversion of j formation 6 suitably comprises a recombination reaction in the presence of sodium hypogasate and methanol. In one embodiment, the compound and the alcohol R4〇H may be at a ratio of about 1 (rc or less, preferably 5). (: stirring at the following temperature, followed by an aqueous solution of an alkali metal hypoalkite (usually sodium hypochlorite) The reaction is carried out at a rate to maintain the internal temperature below 1 Torr. The reaction can then be stirred at 5 ° C for a period of time, usually 3 Torr. Then by adding a base such as an alkali metal hydroxide, usually hydrating The solution (in a charged reaction at a rate to maintain the internal temperature below about 1 G ° C) to verify the reactants comprising the N-gas guanamine intermediate. The reaction temperature can then be maintained below 1 (rc) For a period of time, usually about 3 minutes, the temperature of the reactants is then adjusted to about 2 (TC to about 3 (in the range of rc, typically 2 rc. This temperature can then be maintained in the range of about 15 hours to about 30 hours, usually A period of from about 20 hours to about 25 hours, followed by adjustment of the reactants to a temperature below 10 ° C, typically about 5 ° C, followed by loading of an acid such as hydrochloric acid, and maintaining the temperature of the resulting suspension at about , lasting at least (one), time. Then you can pass #filter product and water Methanol (usually 1:1, KOi MeOH) is washed and dried in vacuo to give compound B as a white crystallite solid. For example, the product can be purified by recrystallization to form a conversion product of B. It can be present in a mixture of water and 2-propanol. Recrystallization is achieved. According to another aspect of the invention, there is provided a method of producing a compound of formula j as defined above. The method comprises converting a compound of formula π to a compound of formula 1, wherein R丨, R2 and I have the same as above Given the same meaning of 135964.doc 200927740.

在一實施例中,Ri、R2及R3之至少一者為氟。在一實施 例中,式II化合物具有式IIAIn one embodiment, at least one of Ri, R2, and R3 is fluorine. In one embodiment, the compound of formula II has formula IIA

„A„A

F π形成i之轉化可包含在無機酸及有機酸存在下水解。無 機酸可為硫酸。有機酸可為乙酸。反應介質可為乙酸與硫 ❹ 酸之混合物。 在一實施例中,在約15°c至約25t範圍内,通常約20〇c 之溫度下伴隨攪拌將無機酸添加至有機酸中之化合物π。 接著可將反應物溫度增加至約8〇t至約11〇。〇範圍内,通 常約1〇〇。。之溫度,且將該溫度維持一段時間,通常約45_ 90。(例如60)分鐘。接著可將反應物之溫度降至約饥至約 3 5 C範圍内’通常約3 〇。之溫度且經一段時間(通常約2〇分 鐘)將含水醇(諸如含水異丙醇(通常2:1,水:ιρΑ)裝入反應 ® 物中。接著可將反應物之溫度降至低於HTC之溫度(通常 5。〇 ’且維持在此溫度至少2小時。接著可過濾產物且再 以含水醇溶液(諸如含水異丙醇(通常2:1,水:ιρΑ)、醇及 驗(諸如驗金屬氫氧化物,較佳氫氧化鉀溶液)之水溶液及 最終再以含水醇溶液(諸如含水異丙醇(通常Η,水:叫 洗蘇濾餅。接著可將產物在約贼真空乾燥得到化合物 I ° 在一實施例中,該方法如下所示。 135964.doc 200927740 ΟThe conversion of F π to form i may comprise hydrolysis in the presence of a mineral acid and an organic acid. The inorganic acid can be sulfuric acid. The organic acid can be acetic acid. The reaction medium can be a mixture of acetic acid and sulfuric acid. In one embodiment, the mineral acid is added to the compound π in the organic acid with stirring at a temperature of from about 15 ° C to about 25 t, typically about 20 ° C. The temperature of the reactants can then be increased to between about 8 Torr and about 11 Torr. Within the scope of 〇, it is usually about 1 〇〇. . The temperature is maintained for a period of time, typically about 45-90. (eg 60 minutes). The temperature of the reactants can then be lowered to about hunger to about 35 C', typically about 3 Torr. At a temperature and for a period of time (usually about 2 minutes) an aqueous alcohol (such as aqueous isopropanol (usually 2:1, water: ιρΑ) is charged to the reaction product. The temperature of the reactants can then be lowered below The temperature of the HTC (usually 5. 〇' and maintained at this temperature for at least 2 hours. The product can then be filtered and then treated with an aqueous alcohol solution (such as aqueous isopropanol (usually 2:1, water: ιρΑ), alcohol and test (such as An aqueous solution of a metal hydroxide, preferably a potassium hydroxide solution, and finally an aqueous alcohol solution (such as aqueous isopropanol (usually hydrazine, water: called a sulphur cake). The product can then be dried under vacuum in a thief. Compound I ° In one embodiment, the method is as follows. 135964.doc 200927740 Ο

RR

NH2 FNH2 F

IIA IA 如上所定義之式II化合物可藉由將式III化合物 R2IIA IA A compound of formula II as defined above may be obtained by formulating a compound of formula III R2

OHOH

III ❹ 轉化成式II化合物而製備,其中Ri、及R3具有如上文所 給出之相同意義。III ❹ is prepared by conversion to a compound of formula II wherein Ri, and R3 have the same meanings as given above.

在一實施例中,R!、尺2及R3之至少一者為氟。在一實施 例中,式III化合物具有式IIIAIn one embodiment, at least one of R!, Ruler 2, and R3 is fluorine. In one embodiment, the compound of formula III has formula IIIA

IIIA III形成II之轉化包括環化縮合反應,諸如在1,4-重氮雙 Ο 環[2.2.2]辛烷(DABCO)存在下使式III化合物與丙稀腈反 應。可將反應混合物加熱至高溫,例如50。(:至90°C範圍 内,較佳60°C至80°C範圍内,更佳約70°C之溫度。該反應 可在純丙烯腈中或使用諸如乙腈或DMF之溶劑進行。 式III化合物可藉由將式IV化合物The conversion of IIIA III to Form II includes a cyclization condensation reaction such as reacting a compound of formula III with acrylonitrile in the presence of 1,4-diazabiindole [2.2.2] octane (DABCO). The reaction mixture can be heated to a high temperature, such as 50. (: to a temperature in the range of 90 ° C, preferably in the range of 60 ° C to 80 ° C, more preferably about 70 ° C. The reaction can be carried out in pure acrylonitrile or using a solvent such as acetonitrile or DMF. Compounds can be obtained by formulating compounds of formula IV

轉化成式ΠΙ化合物而製備,其中Rl、Rz及&具有如上文所 135964.doc 13- 200927740 ijU I 龙 ” 不目同思'義。在一實施例中,R丨、Rz及R3之至少一者Prepared by conversion to a hydrazine compound, wherein R1, Rz and & have the same meaning as 135964.doc 13-200927740 ijU I dragon above. In one embodiment, at least R丨, Rz and R3 One

’、’、°在一實施例中,式I化合物具有式IVA', ', ° In one embodiment, the compound of formula I has formula IVA

F IVA IV形成III之轉化可包括使式IV化合物與曱醯化劑反應。 在一實施例中’該反應在酸存在下進行。該甲醯化劑可為 ❹ 六亞甲基四胺且該酸可為三氟乙酸。 添加甲醯化劑之後,可將反應混合物之溫度升高,例如 升高至6〇t至100°c範圍内,較佳7〇t至9CTC範圍内之溫 度更佳升向至約80°C之溫度。可將此溫度維持一段時 門例如至少60分鐘。可將反應混合物之溫度進一步升高 至約90 C至約130。(:範圍内,較佳約1〇(rc至約12〇c>c範圍内 之溫度,更佳升高至約115。〇之溫度。接著可將反應物冷 卻。’例如冷卻至約HTC至約45。(:範_,較佳約赃至約 ❹ 35t範圍内’更佳約30。°之溫度。可添加水以生成懸浮 液。可過滤懸浮液且再以水洗務。經洗條之懸浮液可直接 用於生成式11化合物,亦即不經單獨的分離步驟。 在-實施例中,本發明提供製備如下所示式从化合物 之方法。Conversion of F IVA IV to Form III can include reacting a compound of Formula IV with a oximation agent. In one embodiment, the reaction is carried out in the presence of an acid. The formazonating agent can be hexamethylenetetramine and the acid can be trifluoroacetic acid. After the addition of the formazan, the temperature of the reaction mixture may be raised, for example, to a range of from 6 Torr to 100 ° C, preferably from 7 Torr to 9 CTC, preferably to about 80 ° C. The temperature. This temperature can be maintained for a period of time, for example, at least 60 minutes. The temperature of the reaction mixture can be further raised to from about 90 C to about 130. (In the range, preferably about 1 Torr (r to about 12 〇c> c, the temperature is more preferably raised to about 115. The temperature of 〇. The reactant can then be cooled. ' For example, cooling to about HTC to Approximately 45. (: Fan _, preferably from about 赃 to about t 35t. More preferably about 30. °. Water may be added to form a suspension. The suspension may be filtered and washed with water. The suspension can be used directly to form the compound of formula 11, i.e., without a separate separation step. In the examples, the invention provides a method of preparing a compound of the formula shown below.

135964.doc • 14- 200927740 更特疋S之,本發明之方法可包括以下步驟:135964.doc • 14- 200927740 More specifically, the method of the present invention may include the following steps:

00

根據本發明之另一態樣’提供製備式B化合物之方法A method of preparing a compound of formula B according to another aspect of the invention

B 5玄方法包含將式V化合物The B 5 mysterious method comprises a compound of formula V

轉化成式B化合物,其中Ri、尺2及1為相同或不同且表示 氫、齒素、烷基、烷基氧基、羥基、硝基、烷基羰基胺 基、烷基胺基或二烷基胺基;且尺4為烷基或芳基,其中: 術语烷基意謂直鏈或支鏈、含有一至六個碳原子、視情況 經芳基、烷氧基、齒素、烷氧羰基或羥基羰基取代之烴 鏈;術語芳基意謂視情況經烷基氧基、自素或硝基取代之 苯基或萘基;且術語_素意謂氟、氣、溴或碘。 在一實施例中,Rl、化及心之至少—者為氟。在另一實 施例中,化合物V具有下式 135964.doc •15· 200927740 ΟConversion to a compound of formula B wherein Ri, scales 2 and 1 are the same or different and represent hydrogen, dentate, alkyl, alkyloxy, hydroxy, nitro, alkylcarbonylamino, alkylamino or dialkyl An amino group; and the quaternary 4 is an alkyl or aryl group, wherein: the term alkyl means straight or branched, containing from one to six carbon atoms, optionally aryl, alkoxy, dentate, alkoxy A hydrocarbon chain substituted with a carbonyl group or a hydroxycarbonyl group; the term aryl means a phenyl or naphthyl group optionally substituted with an alkyloxy group, a self- or a nitro group; and the term _ means means fluorine, gas, bromine or iodine. In one embodiment, at least Rl, chemistry, and heart are fluorine. In another embodiment, compound V has the formula 135964.doc •15· 200927740 Ο

Ν- 在一實施例中,心為^至 基或第三丁基。R4fe佳為甲& = R4視情況為曱基、乙 基。 在另一實施例中,r4為苄 ❹ 在一實施例中,該方法如下所示。Ν - In one embodiment, the heart is a ^ or a butyl group. R4fe is preferably A & = R4, depending on the case, thiol and ethyl. In another embodiment, r4 is benzyl hydrazine. In one embodiment, the method is as follows.

^ F Vi?vV^/NHC02Me^ F Vi?vV^/NHC02Me

W V形成B之轉化法可包括在如机〇h之 上文所給出之相同意義)存扃 八中Ri、有如 中,該熱分解包括庫爾提斯重:進反π解。在一實施例 V化合物溶於有機溶劑 娜k括將式 之回汽、”… 合物加熱至有機溶劑 广皿度。適合之溶劑包括任何實質上惰性 劑’例如二氣甲炫、甲苯或乙酸乙醋。或者,可將如式 啊之㈣作溶劑以及試劑。化合物溶於有機溶敎 過私可在南溫下,例如在3 5 0Ρ Φ δ η 0〇 * 』在35(:至8〇(: ’較佳耽至70t範 圍内之溫度下,較佳在約6〇。〇之溫度下進行。 反應完成後,可將反應混合物冷卻,視情況濃縮且添加 第二有機溶劑,使式B化合物結晶。第二有機溶劑可為任 何飽和烴溶劑,例如石油醚、己烷或庚烷。若第一有機溶 劑可與水混溶’則可添加水’使式B化合物結晶。可冷卻 135964.doc •16- 200927740 至3 〇 C以下,較佳為15 °C以下之溫度。 應瞭解0完基環中之董;§ ·5τ cj ru 之氧原子T以CH2基團或s原子置換, 使得環結構分別成為萘基環或硫π完基環,且V形成B之轉 化法可依上文關於。完基環所述之相同方式進行。 根據本發明之另一態樣,提供製備如上所定義式V化合 物之方法。該方法包括將式VI化合物The conversion method in which W V forms B may include the same meaning as given above in the case of the machine h), in the case of Ri, as in the case, the thermal decomposition includes the Kurtis weight: the inverse π solution. In a compound of Example V, the compound is dissolved in an organic solvent, and the compound is heated to an organic solvent. Suitable solvents include any substantially inert agent such as dioxane, toluene or acetic acid. Ethyl acetate. Alternatively, the formula (4) can be used as a solvent and a reagent. The compound is dissolved in the organic solvent and can be used at a south temperature, for example, at 3 5 0 Ρ Φ δ η 0〇* 』 at 35 (: to 8 〇) (: 'It is preferably at a temperature in the range of 70 Torr, preferably at a temperature of about 6 Torr. After the reaction is completed, the reaction mixture can be cooled, concentrated as appropriate and a second organic solvent is added to make Formula B Crystallization of the compound. The second organic solvent can be any saturated hydrocarbon solvent, such as petroleum ether, hexane or heptane. If the first organic solvent is miscible with water, then water can be added to crystallize the compound of formula B. It can be cooled 135,964. Doc •16- 200927740 to 3 〇C or less, preferably a temperature below 15 ° C. It should be understood that the oxygen atom T of the 5 c cj ru is replaced by a CH 2 group or s atom, so that The ring structure becomes a naphthyl ring or a sulfur π-complete ring, respectively, and V forms B. Above for the conversion process to follow. After the same manner as the base for the ring. According to another aspect of the present invention, there is provided a process for preparing a compound of formula V as defined above, the composition. The method comprises the compound of formula VI

ΟΗΟΗ

VI 轉化成式V化合物,其中Ri、1及尺3具有如上文所給出之 相同意義。VI is converted to a compound of formula V wherein Ri, 1 and 3 have the same meaning as given above.

在一實施例中,Rl、R2及R3之至少-者為氟。在一實施 例中’式VI化合物具有式VIAIn one embodiment, at least one of R1, R2, and R3 is fluorine. In one embodiment, the compound of formula VI has formula VIA

VIA 〇 VI形成V之轉化可包括通常在可與水混溶之溶劑及視情 況鹼存在下使用醯基疊氮化物形成劑,該醯基疊氮化物形 成劑之實例為熟習該項技術者所熟知。亦可存在水。 醯基疊氮化物形成劑可為在鹼存在下之二苯基磷醯基疊 氣化物。可與水混溶之溶劑可為丙酮、乙腈、DMF、 THF、二噁烷或丨,2_二曱氧基乙烷。鹼較佳為弱鹼且可為 三乙基胺、三丙基胺或三丁基胺。 例如藉由向反應混合物添加冷水,可使式V化合物自其 135964.doc •17· 200927740 沈殿。接著可將懸浮液冷卻,過滤且以適合 取濕減餅。化合物¥於萃取有機溶劑中的溶液可如:所述 直接用於轉化為Β,亦即不經單獨的分離步驟。 /瞭解°完基環中之氧原子可以叫基團或s原子置換使 仔壤結構分別成為萘基環或"基環,且VI形成k 化可以如上文關於絲環所述之相同方式進行。轉 Ο ❿ 根據本發明之另—態樣,提供製備如上所定義式VI化合 物之方法。該方法包括將式II化合物 轉化成式V丨化合物,其+R|、m3具有如以所 相同意義。 在一實施例中,R1、m3之至少—者為1在_實施 例中,式II化合物具有式ΠΑThe conversion of VIA 〇VI to form V may include the use of a sulfhydryl azide former typically in the presence of a water miscible solvent and optionally a base, examples of which are those skilled in the art. Well known. Water can also be present. The mercapto azide forming agent may be a diphenylphosphonium-based lamination in the presence of a base. The water-miscible solvent may be acetone, acetonitrile, DMF, THF, dioxane or hydrazine, 2-dimethoxy ethane. The base is preferably a weak base and may be triethylamine, tripropylamine or tributylamine. For example, by adding cold water to the reaction mixture, the compound of formula V can be made from its 135964.doc •17·200927740. The suspension can then be cooled, filtered and adapted to take the wet cake. The solution of the compound in the extraction of the organic solvent can be directly used for conversion to hydrazine as described, i.e., without a separate separation step. /Understanding that the oxygen atom in the ring can be called a group or s atom substitution, so that the structure of the seedlings becomes a naphthyl ring or a "base ring", and the formation of VI can be carried out in the same manner as described above with respect to the wire ring. . Conversion Ο According to another aspect of the invention, there is provided a process for the preparation of a compound of formula VI as defined above. The method comprises converting a compound of formula II to a compound of formula V wherein +R|, m3 have the same meaning. In one embodiment, at least one of R1, m3 is 1 in the embodiment, the compound of formula II has the formula

ΙΙΑ 11形成vl之轉化可包括使具有式η之腈水解。水解可包 括式II化合物與驗(諸如氫氧化納、氫氧化链或氢氧化钟) 在Κ存在下反應’隨後以酸(諸如鹽酸、硫酸或磷酸)處 理。 應瞭解。完基環中之氧原子可以CH2基團或S原子置換 得環結構分別成為萘基環或硫。完基環,且II形成VI之轉 135964.doc -18· 200927740 亦即藉由將式 化可以如上文關於咣基環所述之相同方式進_ 式II化合物可根據上文所述之方法製備, III化合物 相同意義 ❹The formation of ΙΙΑ 11 to form a conversion of vl can include hydrolyzing a nitrile having the formula η. Hydrolysis can involve treatment of a compound of formula II with a test such as sodium hydroxide, hydroxide or hydrazine in the presence of hydrazine followed by treatment with an acid such as hydrochloric acid, sulfuric acid or phosphoric acid. Should understand. The oxygen atom in the ring can be replaced by a CH2 group or an S atom to obtain a naphthyl ring or sulfur, respectively. Completion of the base ring, and II formation of VI turn 135964.doc -18· 200927740, that is, by formulating the compound in the same manner as described above for the fluorenyl ring, the compound of formula II can be prepared according to the method described above. , III compounds have the same meaning❹

DD

出之 式III化合物可根據上文所述之方法製備,亦即藉由將式 IV化合物The compound of formula III can be prepared according to the method described above, that is, by the compound of formula IV

r3 OH IV 轉化成式III化合物’其中Rl、尺2及尺3具有如上文 相同意義。 所給出 之 之 在一實施例中,本發明提供如下所示製備式B化合物 方法。 i) Η) in)Conversion of r3 OH IV to a compound of formula III wherein R1, 尺2 and 尺3 have the same meaning as above. In one embodiment, the invention provides a method of preparing a compound of formula B as shown below. i) Η) in)

OHOH

iv) a) iv) b) NHC02Me 上述步驟之適當反應條件為 135964.doc •19- 200927740 i)三氣乙酸’六亞甲基四胺’ 8〇°c隨後urc,水. :二曱基甲酿胺,丙稀猜…氮雙環[2咖 水,7 0 C ; iii)a)氫氧化鈉,水,95t: ; b)濃鹽酸; 1V)a)丙嗣,三乙基胺,二笨基磷醯基疊敗化物水二 氣甲烷’甲醇,60°C,石油醚。 本發明方法中之所有步驟均安全且經濟並得到良好 之產物。 在一實施例中,可將根據本發明方法之任一方法製備之 式B化合物轉化成式E化合物Iv) a) iv) b) NHC02Me The appropriate reaction conditions for the above steps are 135964.doc •19- 200927740 i) Tri-acetic acid 'hexamethylenetetramine' 8 〇 °c followed by urc, water. : Diterpene Amine, propylene guess... nitrogen bicyclo [2 coffee water, 70 C; iii) a) sodium hydroxide, water, 95t: ; b) concentrated hydrochloric acid; 1V) a) propanil, triethylamine, two stupid Phosphate-based ruthenium compound water two-gas methane 'methanol, 60 ° C, petroleum ether. All of the steps in the process of the invention are safe and economical and result in good products. In one embodiment, a compound of formula B prepared according to any of the methods of the invention can be converted to a compound of formula E.

Ε 其中Ru表示氫、烷基或烷基芳基;11為1、2或3 ;且心、 I及R3具有如上文所給出之相同意義。式E化合物可為具 ❹ 有式P之化合物 s.、Ε wherein Ru represents hydrogen, alkyl or alkylaryl; 11 is 1, 2 or 3; and the cores, I and R3 have the same meanings as given above. The compound of formula E can be a compound having the formula P s.,

-NH-NH

PP

NH2HCI 該轉化可包括以下步驟。將式B化合物轉化成式A化合 物之S或R對映異構體, 135964.doc •20- 200927740NH2HCI This conversion can include the following steps. Conversion of a compound of formula B to the S or R enantiomer of a compound of formula A, 135964.doc • 20-200927740

R4 A 其中Ri义2、&3及R4具有如上文所給出之相同意義。 在一實施例中,Rl、心及1之至少一者為氟。化合物A 適當地具有下式:R4 A wherein Ri, 2, & 3 and R4 have the same meanings as given above. In one embodiment, at least one of R1, heart, and 1 is fluorine. Compound A suitably has the formula:

在一實施例中,R4為(^至匕烷基。t視情況為甲基、乙 基或tBu。R4較佳為曱基。在另一實施例中,I為爷基。 在一實施例中,化合物八呈S對映異構體形式。在另-實施例中,化合物A呈R對映異構體形式。 可將化合物A之R或S對映異構體轉化成式c化合物或其 鹽之相應R或S對映異構體。In one embodiment, R4 is (^ to decyl. t is optionally methyl, ethyl or tBu. R4 is preferably fluorenyl. In another embodiment, I is aryl. In an embodiment Wherein compound VIII is in the S enantiomer form. In another embodiment, compound A is in the R enantiomer form. The R or S enantiomer of compound A can be converted to a compound of formula c or The corresponding R or S enantiomer of its salt.

其中Rr I及&具有如上文所給出之相同意義。可將式c 化合物或其鹽之尺或8對映異構體轉化成式e化合物或其鹽 之相應R或S對映異構體 &Wherein Rr I and & have the same meaning as given above. The compound of formula c or a salt thereof or an enantiomer of the same may be converted to the corresponding R or S enantiomer of a compound of formula e or a salt thereof;

其中Rf、I及R3具有如上文所給出之相同意義 135964.doc •21 - 200927740 氫、烷基或烷基芳基;且η為1、2或3。 Ε較佳為(R)-5-(2-胺基乙基)-1-(6,8-二氟咣啶-3_基 二氣。米吐-2 -琉嗣。 在一實施例中,使式C化合物之R或S對映異構體與式D2 化合物Wherein Rf, I and R3 have the same meaning as given above 135964.doc • 21 - 200927740 hydrogen, alkyl or alkylaryl; and η is 1, 2 or 3. Preferably, hydrazine is (R)-5-(2-aminoethyl)-1-(6,8-difluoroacridin-3-yldialdehyde. Met-2-oxime. In one embodiment , the R or S enantiomer of the compound of formula C and the compound of formula D2

D2D2

與水溶性硫氰酸鹽在有機酸存在下在實質上惰性溶劑中反 應’隨後脫除中間產物F至I之保護基:Reacting with a water-soluble thiocyanate in the presence of an organic acid in a substantially inert solvent. Subsequent removal of the protecting group of intermediates F to I:

S^NH 4ScrNi NR12R13S^NH 4ScrNi NR12R13

從而生成式E化合物或其里之相應對"構想Thus generating a compound of formula E or its corresponding pair"

S.S.

E 135964.doc -22- 200927740 其中Ri、R2及R3具有如上文所給出之相同意義,η表示i、 2或3 ; Ru表示氫、烷基或烷基芳基’ 1^1表示羥基保護基 且!^3表示胺基保護基,或Rll係如上文所定義但與Is 一起表示醜醯亞胺基(phthalimido)。 水溶性硫氰酸鹽較佳為鹼金屬硫氰酸鹽或硫氰酸四烷基 銨。溶劑較佳為有機溶劑。 在 實施例中’η為2或3。在另一實施例中,R^、R2及 R3之至少一者為氟。式E化合物視情況為: (S)-5-(2-胺基乙基)-ΐ·(ΐ,2,3,4-四氫萘_2_基)d,%二氫咪唑· 2 -硫酿]| (8)-5-(2-胺基乙基)-1-(5,7-二氟-1,2,3,4-四氫萘-2-基)-1,3- 二氫咪唑-2-硫酮; (R)-5-(2-胺基乙基)-1-11 克。完-3-基-1,3-二氫咪or坐_2_硫酮; (R)-5-(2-胺基乙基)-1-(6-羥基咣。完-3-基)_ι,3-二氫咪唑-2-硫酮; (R)-5-(2-胺基乙基)-1-(8-羥基咣啶-3-基二氫咪唑-2-硫酮; (R)-5-(2-胺基乙基)-1-(6-甲氧基咬嘵-3-基)-1,3-二氫咪唑-2-硫綱; (R)-5-(2·胺基乙基)-1-(8-曱氧基咬啶·3-基)_ι,3-二氫咪唑_ 2-硫酮; (R)-5-(2-胺基乙基)-1-(6-氟咬σ完-3-基)_ι,3_二氮味σ坐-2 -硫 酮; (R)-5-(2-胺基乙基)-1-(8-乱ρ克°完-3-基)_ι,3_二凰米嗅-2 -硫 135964.doc -23- 200927740 酮; (R) -5_(2_胺基乙基)-1·(6,7 -二氣 ^^-3·基)-l,3 -二氮 口米 °坐-2_ 硫酮; (R) -5-(2-胺基乙基)-1-(6,8_二氣 ^^-3-基)-1,3 -二氯味°坐-2-硫酮; (S) -5_(2_胺基乙基)-1_(6,8 -二氣 ^^-3 -基)_1,3_二虱 σ米嗤·2_ 硫 Sl^, (1^)-5-(2-胺基乙基)-1-(6,7,8-二氣咬〇完-3-基)-1,3-二乳13米。坐· ❹ 2-硫酮; (R) - 5 _(2·胺基乙基)-1-(6 -氣-8-甲氧基 ^^-3 -基)-1,3·二氣 咪唑-2-硫酮; (R)-5-(2 -胺基乙基)_1-(6 -曱氧!基-8 -亂咬σ完·3 -基)-1,3 -二風 咪唑-2-硫酮; (R)_5-(2_胺基乙基)-1-(6 -硝基口克°完-3 -基)·1,3·二風味嗤-2_ 硫嗣, (R)-5-(2-胺基乙基)-1-(8 -硝基口克。完-3-基)-1,3-二乳σ米嗤·2_ 硫酮; (R)-5-(2 -胺基乙基)-1-[6_(乙酿基胺基)^^-3 -基]-1,3·二鼠 咪唑-2-硫酮; (R)-5-胺基曱基-1 口克σ完 3-基-1,3 -二風17米17坐-2-硫網, (R)-5-胺基甲基-1 - (6-經基ρ克11 完-3-基)_1,3·二風°米°坐-2_硫嗣, (R)-5-(2-胺基乙基)-1-(6-經基-7-节基1:7克°完_3·基)-1,3-二氮 咪唑-2-硫酮; (R)-5-胺基甲基-l-(6,8-二氣口克°完-3-基)-1,3·二氣口米°坐-2-硫嗣; 135964.doc •24· 200927740 (R) -5-(3·胺基丙基)-l-(6,8-二氣ΐI克u完_3-基)-l,3-二氮τJ米fl坐-2-硫嗣, (S) -5-(3-胺基丙基)-l-(5,7-二氣-1,2,3,4-四氮蔡-2 -基)-1,3· 二氫咪唑-2-硫酮; (R,S)-5-(2-胺基乙基)-1-(6-經基硫咬°完_3·基)-1,3-二氮味 唑-2-硫酮; (R,S)-5-(2-胺基乙基)-1-(6-甲氧基硫咣垸-3-基)-1,3-二氫咪 唑-2-硫酮; (R)-5-(2-苄基胺基乙基)-1-(6-甲氧基咣嘵-3-基)-1,3-二氫咪 唑-2-硫酮; (尺)-5-(2_午基胺基乙基)-1-(6 -經基咬π完·3·基)-1,3 -二氮味 唑-2-硫酮; (R)-l-(6 -經基咬。完-3 -基)-5_(2-曱基胺基乙基)_1,3 -二風味 唑-2-硫酮; (R)· 1_(6,8_二氣p克。完-3 -基)-5-(2-曱基胺基乙基)·1,3·二氣味 嗤-2 -硫綱或 (R) -1 -咬。完-3 -基-5 - (2-甲基胺基乙基)_1,3_二風ρ米唾-2-硫洞。 式Ε化合物亦可為以下各物之鹽: (S) -5-(2-胺基乙基)-1-(1,2,3,4·四氯秦-2 -基)-1,3 -二氮11米0坐-2-硫酮; (S)-5-(2-胺基乙基)-1·(5,7·二氟-1,2,3,4-四氮蔡-2 -基)-1,3_ 二氫咪唑-2-硫酮; (R)-5-(2 -胺基乙基)-1-^σ完·3·基·1,3 -二風嗦°坐-2-硫嗣; (R)-5-(2·胺基乙基)-1-(6-|^基咬咬-3 -基)_1,3_二氯哺。坐-2- 135964.doc -25- 200927740 硫酮; (R)-5-(2-胺基乙基)-1-(8 -經基 ^^-3-基)-1,3 -二氯 0米 °坐-2_ 硫酮; (R)-5-(2-胺基乙基)-1-(6-甲氧基咣啶-3-基)-1,3-二氫咪唑-2-硫酮; (R)-5-(2-胺基乙基)-1-(8-甲氧基咣咣-3-基)-1,3-二氫咪唑-2-硫酮; (R)-5- (2-胺基乙基)-1-(6 -氣咬°完-3 -基)-1,3-二氮p米吐-2-硫嗣; . (R)-5-(2-胺基乙基)-1-(8-氧咬。完-3-基)-1,3-二氮ρ米π坐-2-硫嗣; (R)-5-(2-胺基乙基)-1-(6,7-二氣ρ克σ完-3-基)-1,3-二氮味 °坐-2- 硫5¾, (R) _5_(2·胺基乙基)-l-(6,8·二風t^:r克π完-3-基)·l,3-二氮σ米σ坐-2-硫酮; (S) -5-(2 -胺基乙基)-1_(6,8 -二乳 p克°完-3·基)-1,3-二風味 坐 _2_ 硫酮; (11)-5-(2-胺基乙基)-1-(6,7,8-三氟咣咣-3-基)-1,3-二氫咪唑- 醫 2-硫酮; (R)-5 - (2 -胺基乙基)-1-(6 -氯-8_曱氧基咬°完-3-基)-1,3 -二氮 咪唑-2-硫酮; (R)-5-(2-胺基乙基)-1-(6-曱氧基-8-氯咬°完_3_基)-1,3-二氯 咪唑-2-硫酮; (1^)_5-(2-胺基乙基)-1-(6-硝基*7克°完-3-基)-1,3-二虱味。坐-2- 硫酮; (R)-5-(2-胺基乙基)-1 ·(8-硝基吹。完 3-基)-1,3 -二鼠味°坐-2_ 135964.doc -26- 200927740 硫酮; (R)-5_(2 -胺基乙基)-1-[6-(乙酿基胺基)咬°完-3 -基]-1,3 -二風 咪唑-2-硫酮; (R)-5·胺基曱基-1 ·口克σ完-3-基-1,3 -二風味°坐-2-硫嗣, (R)_5-胺基甲基-1-(6 -經基咬11 完-3 -基)-1,3-二氯11米嗤_2_硫 酮; (R)-5-(2-胺基乙基)-1-(6 -經基-7·节基味11完-3 -基)-1,3 -二鼠 咪唑-2-硫酮;E 135964.doc -22- 200927740 wherein Ri, R2 and R3 have the same meaning as given above, η represents i, 2 or 3; Ru represents hydrogen, alkyl or alkylaryl '1^1 represents hydroxy protection Base! ^3 represents an amino protecting group, or Rll is as defined above but together with Is represents an phthalimido. The water-soluble thiocyanate is preferably an alkali metal thiocyanate or a tetraalkylammonium thiocyanate. The solvent is preferably an organic solvent. In the embodiment, 'η is 2 or 3. In another embodiment, at least one of R^, R2 and R3 is fluorine. The compound of formula E is optionally as follows: (S)-5-(2-aminoethyl)-oxime (ΐ,2,3,4-tetrahydronaphthalene-2-yl)d, % dihydroimidazole· 2 - Sulfur brewing||(8)-5-(2-Aminoethyl)-1-(5,7-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)-1,3- Dihydroimidazole-2-thione; (R)-5-(2-Aminoethyl)-1-11 g. -3--3-yl-1,3-dihydromiol or sitting _2_thione; (R)-5-(2-aminoethyl)-1-(6-hydroxyindole. -3-yl) _ι,3-dihydroimidazole-2-thione; (R)-5-(2-aminoethyl)-1-(8-hydroxyacridin-3-yldihydroimidazole-2-thione; R)-5-(2-Aminoethyl)-1-(6-methoxybenzo-3-yl)-1,3-dihydroimidazole-2-thios; (R)-5-( 2·Aminoethyl)-1-(8-decyloxyguanidin-3-yl)_ι,3-dihydroimidazole-2-thione; (R)-5-(2-Aminoethyl) -1-(6-fluoro-bito σ-end-3-yl)_ι,3_diazepine σ sit-2-thione; (R)-5-(2-aminoethyl)-1-(8-乱ρ克°完-3-基)_ι,3_二凰米闻-2 - sulfur 135964.doc -23- 200927740 ketone; (R) -5_(2_aminoethyl)-1·(6, 7 - 二气^^-3·yl)-l,3 -diaza methane ° sitting -2_thione; (R) -5-(2-aminoethyl)-1-(6,8_two Gas ^^-3-yl)-1,3-dichloro-flavor °-thiol; (S) -5_(2_aminoethyl)-1_(6,8-digas^^-3 -Base)_1,3_二虱σ米嗤·2_ Sulfur Sl^, (1^)-5-(2-Aminoethyl)-1-(6,7,8-di-gas bite-end-3 -yl)-1,3-di-milk 13 m. Sit · ❹ 2-thione; (R) - 5 _(2·aminoethyl)-1-(6-gas-8-methoxy ^^-3 -yl)-1,3·diazolidine-2-thione; (R)-5-(2-aminoethyl)_1-(6-oxime!--8-bite σ ·3-yl)-1,3-diazol imidazole-2-thione; (R)_5-(2-aminoethyl)-1-(6-nitromethyl gram-fin-3-yl) · 1,3 · two-flavor 嗤-2_ thiopurine, (R)-5-(2-aminoethyl)-1-(8-nitro ke..-3-yl)-1,3-di Milk σ m嗤·2_ thioketone; (R)-5-(2-aminoethyl)-1-[6-(ethyl arylamino)^^-3-yl]-1,3·di-imidazole -2-thione; (R)-5-aminoindenyl-1 gram σ-end 3-yl-1,3-two wind 17 m 17-sodium-sulfur net, (R)-5-amino group Methyl-1 - (6-yl-based p-gram 11-end-3-yl)_1,3·二风°米° sit-2_ thiopurine, (R)-5-(2-aminoethyl)- 1-(6-radio-7-membered group 1:7 g ° ° _3·yl)-1,3-diazaimidazole-2-thione; (R)-5-aminomethyl-l- (6,8-two gas mouth gram ° complete -3- base) -1,3 · two gas mouth meters ° sit-2-sulfurium; 135964.doc •24· 200927740 (R) -5-(3·aminopropyl Base)-l-(6,8-dione ΐI 克u _3-yl)-l,3-diaza τJ-m fl-sodium-2-thioindole, (S) -5-(3-aminopropyl Base)-l-(5,7-di-gas-1,2,3,4-tetrazane-2 -yl)-1,3·dihydroimidazole-2 -thione; (R,S)-5-(2-aminoethyl)-1-(6-sulfanylsulfonate _3·yl)-1,3-diazosazole-2-sulfur Ketone; (R,S)-5-(2-aminoethyl)-1-(6-methoxythiazol-3-yl)-1,3-dihydroimidazole-2-thione; R)-5-(2-benzylaminoethyl)-1-(6-methoxyindol-3-yl)-1,3-dihydroimidazole-2-thione; (foot)-5 -(2_n-ylaminoethyl)-1-(6-trans-substrate π-end·3·yl)-1,3-diazosazole-2-thione; (R)-l-(6 - bite through the base. -3 -yl)-5-(2-decylaminoethyl)_1,3-di-flavonol-2-thione; (R)·1_(6,8_二气p克。完-3 - Base) 5-(2-mercaptoaminoethyl)·1,3·diodor oxime-2-sulfo or (R)-1-bit. Complete -3 -yl-5 - (2-methylaminoethyl)_1,3_two wind ρ m sal -2- sulfur hole. The hydrazine compound may also be a salt of the following: (S) -5-(2-aminoethyl)-1-(1,2,3,4·tetrachloroqin-2-yl)-1,3 - dinitrogen 11 m 0 sit-2-thione; (S)-5-(2-aminoethyl)-1·(5,7·difluoro-1,2,3,4-tetrazine- 2-(yl)-1,3_dihydroimidazole-2-thione; (R)-5-(2-aminoethyl)-1-^σ·3·yl·1,3 -two wind 嗦° Sodium-2-thioindole; (R)-5-(2.Aminoethyl)-1-(6-|^-based bite-3-yl)_1,3_dichlorofeed. Sitting -2- 135964.doc -25- 200927740 thioketone; (R)-5-(2-aminoethyl)-1-(8-transyl^^-yl)-1,3-dichloro 0 m ° sit-2_thione; (R)-5-(2-aminoethyl)-1-(6-methoxyacridin-3-yl)-1,3-dihydroimidazole-2- (R)-5-(2-Aminoethyl)-1-(8-methoxyindol-3-yl)-1,3-dihydroimidazole-2-thione; (R) -5-(2-Aminoethyl)-1-(6-gasbitate-end-3-yl)-1,3-dinitro-p-tiprop-2-thioindole; (R)-5-( 2-Aminoethyl)-1-(8-oxo-bit.--3-yl)-1,3-diaza-p-m-pyridin-2-thioindole; (R)-5-(2-amino group Ethyl)-1-(6,7-dioxo ρg σ -3--3-yl)-1,3-diaza scent ° sulphur -5⁄4, (R) _5_(2·aminoethyl) -l-(6,8·二风t^:rg π完-3-yl)·l,3-diazo σm σ sit-2-thione; (S) -5-(2-amino group Ethyl)-1_(6,8-di-milk p-g -3 -yl)-1,3-di-flavored _2_thione; (11)-5-(2-aminoethyl)-1 -(6,7,8-trifluoroindol-3-yl)-1,3-dihydroimidazole-medicine 2-thione; (R)-5 - (2-aminoethyl)-1-( 6-Chloro-8-oxime-biting -3-yl)-1,3-diazolidine-2-thione; (R)-5-(2-aminoethyl)-1-(6 -曱oxy-8- Biting ° _3_ base)-1,3-dichloroimidazole-2-thione; (1^)_5-(2-aminoethyl)-1-(6-nitro*7 g °- 3-based)-1,3-dioxin. Sodium-2-thione; (R)-5-(2-aminoethyl)-1 ·(8-nitro blowing. 3-yl)-1,3 - two rat taste ° sitting -2 135964. Doc -26- 200927740 thioketone; (R)-5-(2-aminoethyl)-1-[6-(ethyl arylamino) bite-end-3-yl]-1,3-diazolidine (2-)-thiol-1; Base-1-(6-trans-base bit 11--3-yl)-1,3-dichloro-11 m嗤_2_thione; (R)-5-(2-aminoethyl)-1- (6 - thio--7-based base 11-end-3-yl)-1,3-di-imidazole-2-thione;

(R)-5_胺基曱基-1·(6,8_二氣 ^^-3·基)-1,3 -二風 13米哇-2·硫 酮; (R) -5-(3-胺基丙基)-1-(6,8-二氟咬。完-3-基 硫酮; (S) -5-(3-胺基丙基)-1-(5,7·二敗-1,2,3,4-四風秦-2-基)-1,3· 二氫咪唑-2-硫酮; (R,S)-5-(2-胺基乙基)-1-(6•羥基硫咣。完-3·基)-1,3_二氫咪 。坐-2 -硫明, (R,S)-5-(2 -胺基乙基)-1-(6-曱乳基硫咬°完-3-基)-1,3 -二風味 唑-2-硫酮; (R)-5-(2 -节基胺基乙基)-1-(6-曱氧基^^-3·基)·1,3·二氯p米 唑-2-硫酮; (&)-5-(2-节基胺基乙基)-1-(6-經基咬17完-3-基)-1,3-二氮17米 唑-2-硫酮; (R)-1-(6 -經基咬咬-3-基)-5-(2-甲基胺基乙基)-1,3 -二氮味 唑-2胃硫酮; 135964.doc -27- 200927740 (R)-l-(6,8-二氟咣啶_3_基)·5_(2·甲基胺基乙基)1%二氫咪 唾-2 -硫酮或 (R)-l-咣啶-3-基-5-(2-甲基胺基乙基卜匕弘二氫咪唑_2_硫 酮.。該鹽較佳為鹽酸鹽。 根據本發明之另一態樣,提供式丨化合物 〇(R)-5-aminomercapto-1(6,8_diox^^-3.yl)-1,3-two wind 13 mw-2·thione; (R) -5-( 3-aminopropyl)-1-(6,8-difluorobitate. -3-ylthione; (S) -5-(3-aminopropyl)-1-(5,7·2 -1,2,3,4-tetrahydroqin-2-yl)-1,3. dihydroimidazole-2-thione; (R,S)-5-(2-aminoethyl)-1 -(6•hydroxy thiopurine. End-3·yl)-1,3_dihydromime. Sodium-2 - thiophene, (R,S)-5-(2-aminoethyl)-1-( 6-曱 基 硫 硫 ° °-3-yl)-1,3-di-flavon-2-thione; (R)-5-(2-arylaminoethyl)-1-(6-曱oxy^^-3·yl)·1,3·dichlorop-mazole-2-thione; (&)-5-(2-pyrylaminoethyl)-1-(6- Substrate 17--3-yl)-1,3-diaza 17-mazole-2-thione; (R)-1-(6-trans-bito-3-yl)-5-(2-A Aminoethyl)-1,3-diazosazole-2 stomach thione; 135964.doc -27- 200927740 (R)-l-(6,8-difluoroacridine_3_yl)·5_ (2·Methylaminoethyl) 1% dihydromiprofen-2-thione or (R)-l-acridin-3-yl-5-(2-methylaminoethyldipyridinium dihydrogen Imidazole 2 -thione. The salt is preferably a hydrochloride. According to another aspect of the invention, Shu compound billion

NH2 J ❹ ” 其中Ri、R2及R3為相同或不同且表示氫、鹵素、烷基、烷 基氧基、羥基、硝基、烷基羰基胺基、烷基胺基或二烷基 胺基,其中.術語烧基意謂直鏈或支鏈、含有一至六個碳 原子、視情況經芳基、烷氧基、函素、烷氧羰基或羥基羰 基取代之烴鏈;術語芳基意謂視情況經烷基氧基、齒素或 硝基取代之苯基或萘基;且術語鹵素意謂氟、氣、溴或NH2 J ❹ " wherein Ri, R2 and R3 are the same or different and represent hydrogen, halogen, alkyl, alkyloxy, hydroxy, nitro, alkylcarbonylamino, alkylamino or dialkylamino, Wherein the term alkyl radical means a straight or branched chain hydrocarbon chain containing from one to six carbon atoms, optionally substituted with an aryl group, an alkoxy group, a functional group, an alkoxycarbonyl group or a hydroxycarbonyl group; the term aryl means a phenyl or naphthyl group substituted with an alkyloxy group, a dentate or a nitro group; and the term halogen means fluorine, gas, bromine or

碘。在一實施例中,Rl、心及化之至少一者為氟。化合物 ❹ 1適當地具有下式IAiodine. In one embodiment, at least one of R1, heart, and chemistry is fluorine. The compound ❹ 1 suitably has the following formula IA

化合物1可藉由任何適合之方法(例如藉由上文所述方法 之任一者)製備。 根據本發明之另一態樣,提供式II化合物 135964.doc -28- 200927740Compound 1 can be prepared by any suitable method, such as by any of the methods described above. According to another aspect of the invention, a compound of formula II is provided 135964.doc -28- 200927740

其中Rl、R2及R3具有如上文所給出之相同意義。式π化合 物可根據上文所述方法之任一者製備。化合適當地^ 有下式ΙΙΑWherein R1, R2 and R3 have the same meaning as given above. Formula π compounds can be prepared according to any of the methods described above. Suitable for local ^

FF

根據本發明之另一態樣,提供式V化合物 0According to another aspect of the invention, a compound of formula V is provided

其中R,、R2及R3具有如上文所給出之相同意義。式¥化合 物可根據上文所述方法之任一者製備。化合物V適當地具 有下式Wherein R, R2 and R3 have the same meanings as given above. The compound of the formula can be prepared according to any of the methods described above. Compound V suitably has the following formula

根據本發明之另一態樣,提供式VI化合物According to another aspect of the invention, a compound of formula VI is provided

VI 其中心鳴及〜具有如上文所給出之相同意義。㈣化合 物可根據上文所述方法之任-者製備。化合物vm當地具 135964.doc -29· 200927740 有下式The center of the VI has the same meaning as given above. (d) The compound can be prepared according to any of the methods described above. Compound vm local 135964.doc -29· 200927740

F 現將根據以下非限制性實例描述本發明。 實例 ❹F The invention will now be described in terms of the following non-limiting examples. Example

CO-WCO-W

實例1 : 6,8-二氟-2H-咣啶烯_3_腈-化合物IVA形成化合物 IIIA再形成化合物IIAExample 1: 6,8-Difluoro-2H-acridene-3-nitrile-Compound IVA forming compound IIIA re-forming compound IIA

C6H4F20 MW: 130,09 i) TFA.HMTA ii) DMF, DABCO 丙烯骑C6H4F20 MW: 130,09 i) TFA.HMTA ii) DMF, DABCO propylene ride

C|〇H5F2NO MW: 193,15 將二氟乙酸(11.25 L’ 17.28 kg)及 2,4-二氟笨酌"(IVA, 2.25 kg)裝入100 L反應器中;將所得溶液調節至2〇乞。隨 著良好攪拌’經約30分鐘裝入六亞曱基四胺(2 7〇 kg);使C|〇H5F2NO MW: 193,15 Difluoroacetic acid (11.25 L' 17.28 kg) and 2,4-difluoro stupid " (IVA, 2.25 kg) were charged to a 100 L reactor; the resulting solution was adjusted to 2〇乞. Fill with hexamethylenetetramine (2 7 〇 kg) with good agitation for about 30 minutes;

反應溫度達至40°C。將反應混合物調節至8〇。(:且保持在 80°C歷時至少1.0小時,隨後加熱至115<t。將反應混合物 保持在115 C歷時1 8·0至20.0小時,隨之將反應冷卻至3〇。〇 且經至少30分鐘將水(76.5 L)裝入反應器中。接著將反應 調節至2 C且保持在2°C歷時至少4.0小時。接著過濾所得懸 浮液且以水(18.0 L及13.5 L)洗滌濾餅兩次並接著抽乾歷時 至少3 0分鐘。 接著在以下步驟中使用兩批含水(water wet)搭(ΙΠΑ): 將含水路(ΠΙΑ)、丙烯腈(7.9 kg)、二甲基甲醯胺3.5 135964.doc 200927740 kg)及水(18.5 L)裝入100 L反應器中。隨著良好攪拌,添加 DABCO(〇.88 kg)得到澄清黃色溶液。接著將反應混合物調 節至70C且將反應混合物保持在70。(3歷時18,0至20.0小 時’隨之將反應混合物冷卻至201:。接著裝入水(18.4 L) 且將反應混合物調節至2°C並保持在2。(:歷時3小時。接著 過濾產物,以含水甲醇(7.3 L)(5:l,Me0H:H20)洗滌且於 • 45°C真空乾燥得到呈淺黃色結晶固體之6,8·二氟_2H-吮嗦 烯-3-腈(IIA,2.90 kg,43.5%)。The reaction temperature reached 40 °C. The reaction mixture was adjusted to 8 Torr. (: and kept at 80 ° C for at least 1.0 hour, then heated to 115 < t. The reaction mixture was maintained at 115 C for 1800 to 20.0 hours, followed by cooling the reaction to 3 Torr. Water (76.5 L) was charged to the reactor in minutes. The reaction was then adjusted to 2 C and maintained at 2 ° C for at least 4.0 hours. The resulting suspension was then filtered and the filter cake was washed with water (18.0 L and 13.5 L). And then drained for at least 30 minutes. Then use two batches of water wet (ΙΠΑ) in the following steps: Water-containing road (ΠΙΑ), acrylonitrile (7.9 kg), dimethylformamide 3.5 135964.doc 200927740 kg) and water (18.5 L) were charged to a 100 L reactor. With good agitation, DABCO (〇.88 kg) was added to give a clear yellow solution. The reaction mixture was then adjusted to 70 C and the reaction mixture was maintained at 70. (3 for 18, 0 to 20.0 hours 'The reaction mixture was then cooled to 201:. Water (18.4 L) was then charged and the reaction mixture was adjusted to 2 ° C and kept at 2. (: 3 hours. The product was washed with aqueous methanol (7.3 L) (5:1, EtOAc, EtOAc) and dried in vacuo. (IIA, 2.90 kg, 43.5%).

實例2 . 6,8-一氟-2Η-Ι»克咬稀-3-甲雄胺_化合物ΗA形成化合 物IAExample 2. 6,8-Fluoro-2Η-Ι»克咬稀-3-methylandrostenamine_Compound ΗA forming compound IA

H2S04 AcOH F Ci〇H5F2NO MW: 193,15H2S04 AcOH F Ci〇H5F2NO MW: 193,15

F C10H7F2NO2 MW:211,16 將6,8-二氟-2H-咣嘵烯_3_腈(IIA,2 86 kg)及乙酸(229 〇 L)裝入1〇〇 L反應器中。隨著良好攪拌將所得懸浮液調節 至抓,隨之將硫酸(10.96kg)以單份裝入。接著將所得懸 浮液調節至IGGt且維持在loot歷時6G分鐘。接著將反應 混合物調節至3(TC且經20分鐘裝入含水異丙醇(34 4 L(2.1水·ΙΡΑ))。接著將反應混合物調節至5°c且保持在 5°C歷時至少2.〇小時。接著過滤產物且以含水異丙醇(⑷ L(2.1 ’水:ιΡΑ))、含水〇5 N異丙醇氫氧化鉀溶液 及最终含水異丙醇(14.3 L(2:1,水:IpA))洗蘇遽餅。接著 在真空乾燥產物得到呈微晶固體之6,8_二敗视咬喷 135964.doc -31 · 200927740F C10H7F2NO2 MW: 211,16 6,8-Difluoro-2H-nonene_3_carbonitrile (IIA, 2 86 kg) and acetic acid (229 〇 L) were charged to a 1 〇〇L reactor. The resulting suspension was adjusted to catch with good agitation, and then sulfuric acid (10.96 kg) was charged in a single portion. The resulting suspension was then adjusted to IGGt and maintained at loot for 6 G minutes. The reaction mixture was then adjusted to 3 (TC and charged with aqueous isopropanol (34 4 L (2.1 water·ΙΡΑ)) over 20 minutes. The reaction mixture was then adjusted to 5 ° C and kept at 5 ° C for at least 2. 〇hour. The product was then filtered and treated with aqueous isopropanol ((4) L (2.1 'water: ιΡΑ)), aqueous 〇5 N isopropanol potassium hydroxide solution and finally aqueous isopropanol (14.3 L (2:1, water) :IpA)) Washing the cakes, then drying the product in vacuum to obtain a microcrystalline solid 6,8_2 defeated bite spray 135964.doc -31 · 200927740

稀-3·甲醯胺(ΙΑ,2.91 kg,93.6%)。 實例3、8_二氟-2H_咣嘵烯_3_基胺基甲酸甲酯·化合㈣ 形成化合物BADilute-3·carbamamine (ΙΑ, 2.91 kg, 93.6%). Example 3, 8-difluoro-2H-decene _3-ylaminocarbamate · Compound (IV) Formation of compound BA

MW: 211,16 ChH9F2N03 MW: 241,19 . Ci〇H7F2N〇2 φ 將6,8_二氟孤咬咬稀_3-甲酿胺(以8 kg)及曱醇(44.7 L) 裝入100 L反應器中。隨著良好授掉將所得懸浮液調節至 5°C,隨之以維持㈣溫度低於听之速率裝人次氣酸納 水/合液(8.25 L ’ 1.1當量)。接著將反應混合物在5。〇下授摔 3〇分鐘。對反應混合物取樣且分析以確認起始物質完全耗 盡。接著以維持内部溫度低於1〇。〇之速率裝入15 n氣氧化 納合液(9.3 L)。將反應混合物維持在< 1 〇艽歷時3〇分鐘, 隨後將反應混合物調節至25°C ^反應混合物維持在25〇c歷 ❹ 時2〇.〇至24.0小時。隨之將反應混合物調節至,隨後緩 慢裝入1.5 N鹽酸(2〇.〇 L),將所得懸浮液維持在rc歷時至 少I.0小時。接著過濾產物且以含水曱醇(2x11.5 L(l:l, HzO.MeOH))洗滌並在45°C真空乾燥得到呈白色微晶固體 之6,8-二氟_2Η·咣啶烯-3-基胺基曱酸曱酯(2.45 kg,74.5 %)。 再結晶程序 將水(9.1 L)、2-丙醇(11.4 L)及6,8-二氟-2H-咣咣烯-3_基 胺基甲酸甲酯(2·28 kg)裝入100 L反應器中。隨著良好授掉 135964.doc •32. 200927740 將所得懸浮液調節至75<t且保持在75它直至達成完全溶 解。接著將反應混合物保持在75<t歷時3〇分鐘隨之經6〇 分鐘將反應混合物調節至5 〇 t且保持在5 〇 t歷時6 〇分鐘。 接著經2.0小時將所得懸浮液調節至2<t且保持在2<>c歷時至 少60分鐘。接著過濾產物且以含水2丙醇(2χ68 5, H2〇:IPA))洗滌並在45°C真空乾燥得到呈白色微晶固體之 M-二氟-2H-咣咣烯_3_基胺基甲酸甲酯(2 〇3 kg,88 8 %)。MW: 211,16 ChH9F2N03 MW: 241,19 . Ci〇H7F2N〇2 φ Put 6,8_ difluoroserate bite _3-cartoamine (at 8 kg) and sterol (44.7 L) into 100 In the L reactor. The resulting suspension was adjusted to 5 °C with good transfer, followed by a sub-gas/water mixture (8.25 L '1.1 equivalent) at a temperature below the listening rate. The reaction mixture was then brought to 5. His kneeling was dropped for 3 minutes. The reaction mixture was sampled and analyzed to confirm that the starting material was completely consumed. Then to maintain the internal temperature below 1 〇. The rate of helium was charged with 15 n gas oxidized nano-fluid (9.3 L). The reaction mixture was maintained at < 1 Torr for 3 Torr, then the reaction mixture was adjusted to 25 ° C. The reaction mixture was maintained at 25 ° C for 2 〇. The reaction mixture was then adjusted to the subsequent addition of 1.5 N hydrochloric acid (2 〇.〇 L), and the resulting suspension was maintained at RC for at least 1.0 hour. The product was then filtered and washed with aqueous decyl alcohol (2×11.5 L (1:1, Hz O. MeOH)) and dried in vacuo at 45 ° C to give 6,8-difluoro-2-indole. Ethyl -3-aminoamine decanoate (2.45 kg, 74.5 %). Recrystallization procedure charged with water (9.1 L), 2-propanol (11.4 L) and 6,8-difluoro-2H-nonene-3-ylcarbamic acid methyl ester (2·28 kg) in 100 L In the reactor. With good 135964.doc • 32. 200927740 The resulting suspension was adjusted to 75 < t and held at 75 until complete dissolution was achieved. The reaction mixture was then held at 75 <t for 3 minutes and then the reaction mixture was adjusted to 5 〇t over 6 Torr and held at 5 〇 for 6 〇 minutes. The resulting suspension was then adjusted to 2 < t over 2.0 hours and held at 2 <>> for at least 60 minutes. The product was then filtered and washed with EtOAc (2 EtOAc, EtOAc (EtOAc): EtOAc (EtOAc) Methyl formate (2 〇 3 kg, 88 8 %).

實例4 : 6,8·二氣-2H-咣啶烯_3_腈·化合物IVA至化合物ΙΠΑ 形成化合物IIA 在20°C下向2,4-二氟苯酚(1,〇份重量)於三氟乙酸(5 〇份 體積)中之溶液經30分鐘以分批(piece_meai)方式添加六亞 甲基四胺(1.2份重量,ΐ·ι莫耳當量),同時維持内部溫度 <50°C °接著將反應混合物加熱至8〇°c且維持在此溫度歷 時至少60分鐘。接著將反應混合物加熱至115。(:且維持在 ❿ 此溫度直至藉由HPLC判斷反應完全。接著將反應混合物 冷卻至30它’隨之經3〇分鐘添加水(34.0份體積)得到黃色 懸浮液。接著將懸浮液冷卻至<5。〇且保持在此溫度歷時至 少4.0 h ^接著將懸浮液過濾且隨後再以水(8 〇份體積)洗 蘇。接著在2〇°C下將含水醛吸收於丙烯腈(3.46份體積) 中’隨之添加M-重氮雙環[2.2.2]辛烷(0.24份重量)且將反 應混合物加熱至701。藉由HPLC監控直至反應完全,隨 之在減壓下濃縮反應混合物接近乾燥。將所得漿狀物以含 水甲醇(2·4份體積,17%水)稀釋且冷卻至<5°C歷時2-3 h。 135964.doc -33· 200927740 過濾所得固體且隨後再以人 吸傻冉从含水甲醇(1.0份體積,33%水)洗 膝。接著在45 C真空乾燥標題化合物達恆定重量。 實例5 6’8 —氟_2Η·«Ή埽-3_甲酸_化合物ΠΑ形成化合物Example 4: 6,8·di-gas-2H-acridene_3-nitrile·Compound IVA to compound ΙΠΑ Formation of compound IIA to 2,4-difluorophenol (1, 〇 part by weight) at 20 ° C The solution in fluoroacetic acid (5 parts by volume) was added to hexamethylenetetramine (1.2 parts by weight, ΐ·ι mole equivalent) in batches over 30 minutes while maintaining the internal temperature < 50 ° C The reaction mixture is then heated to 8 ° C and maintained at this temperature for at least 60 minutes. The reaction mixture was then heated to 115. (: and maintained at this temperature until the reaction was judged complete by HPLC. The reaction mixture was then cooled to 30. 'After 3 minutes, water (34.0 parts by volume) was added to give a yellow suspension. The suspension was then cooled to < And kept at this temperature for at least 4.0 h. Then the suspension was filtered and then washed with water (8 liters volume). The aqueous aldehyde was then absorbed in acrylonitrile (3.46 parts) at 2 °C. In the volume, 'M-diazobicyclo[2.2.2]octane (0.24 parts by weight) was added and the reaction mixture was heated to 701. Monitoring by HPLC until the reaction was complete, followed by concentration of the reaction mixture under reduced pressure. Drying. The resulting slurry was diluted with aqueous methanol (2.4 parts by volume, 17% water) and cooled to < 5 ° C for 2-3 h. 135964.doc -33 · 200927740 The resulting solid was filtered and subsequently The human was sucked from the aqueous methanol (1.0 part by volume, 33% water) to wash the knee. The title compound was then dried under vacuum at 45 C to a constant weight. Example 5 6'8-Fluoro 2 Η·«Ή埽-3_carboxylic acid _ compound Ruthenium forming compound

IVAIVA

在2〇°C下,向氫氧化納(〇52份重量,25莫耳當量)於水 (14.0份體積)中之溶液添加M•二氟_2h•咬嘴稀1腈(1〇份 重量),得到懸浮液。接著將反應混合物加熱至机且維 持在95 C直至獲得澄清溶液。接著藉由HpLc監控反應混 &物直到反應元全。接著將反應混合物冷卻至wc且緩慢 添加36%鹽酸(1.31份體積,丨57份重量,3〇莫耳當量)得 到移動懸洋液(mobile suspensi〇np隨後將懸浮液冷卻至 <5C且維持在<5。(:歷時至少^ h。接著將標題化合物過濾 且隨後再以水(2x2.0體積)洗滌。接著在4(rc真空乾燥產物 達恆定重量。 實例6 : 6,8-二氟-2H-咣嗖烯_3-基胺基甲酸甲酯_化合物 VIA形成化合物VA再形成化合物ba 在15°C下,一次添加全量二苯基磷醯基疊氮化物(1」份 體積’ 1.09莫耳當量)至6,8-二氟-2H-咬咬稀-3-甲酸(1.0份 重量)於丙_(1〇.〇體積)及三乙基胺(〇 71份體積,丨〇9莫耳 當量)之溶液中。接著藉由HPLC監控反應混合物直到反應 完全。接著以冷水(20.0份體積)稀釋反應混合物,使中間 體疊氮化物沈殿《將懸浮液冷卻至< 1 〇°C且保持在 <丨〇。〇歷 時1,0 h。接著將懸浮液過濾且隨後再以水(5 〇份體積)洗 蘇。接著將含水濕物質吸收於二氣甲烷(7.5份體積)中且分 135964.doc -34- 200927740 離所得各相。使用硫酸鎮乾燥所得二氣甲燒溶液。接著在 60°C下,W添加速率等於館出物收集之㈣,將二氯甲炫 疊氮化物溶液添加至甲醇(60份體積)中。一旦添加完畢 後,繼續蒸餾直至蒸餾塔頂溫度達60。。,隨之將系統設成 回流。接著藉由HPLC監控反應直至反應完全。接著將反 應混合物冷卻至<15°C且在真空下濃縮至2,〇份體積。接著 以二氣甲烷(7·5份體積)及庚烷(2·5份體積)稀釋粗反應混合 物。接著常壓蒸餾二氣甲烷,將反應混合物濃縮至6.0份 ® 體積。冷卻至25°C後,緩慢添加石油醚(10 0份體積),以 使標題化合物結晶析出。在完全添加後,將所得懸浮液冷 卻至<5°C且保持在5°C歷時1.0 h。接著將標題化合物過濾 且再以石油醚(5.0份體積)洗滌。接著在35°C真空乾燥產物 達怪定重量。 應瞭解本發明可在隨附申請專利範圍之範疇内修改。To a solution of sodium hydroxide (52 parts by weight, 25 moles equivalent) in water (14.0 parts by volume) at 2 ° C, M•difluoro-2h•bite dilute nitrile (1 part by weight) ), a suspension is obtained. The reaction mixture was then heated to an apparatus and maintained at 95 C until a clear solution was obtained. The reaction mixture was then monitored by HpLc until the reaction was complete. The reaction mixture was then cooled to wc and 36% hydrochloric acid (1.31 parts by volume, 丨57 parts by weight, 3 〇 molar equivalent) was slowly added to obtain a mobile suspension (mobile suspensi〇np was subsequently cooled to <5C and maintained) At <5. (: at least ^h. The title compound is then filtered and subsequently washed with water (2 x 2.0 vol). Then the product is dried at 4 (rc vacuum) to a constant weight. Example 6: 6,8-II Fluorin-2H-pinene methyl 3-methylcarbamate - compound VIA to form compound VA to form compound ba at 15 ° C, add the entire amount of diphenylphosphonium azide (1 part by volume) 1.09 molar equivalent) to 6,8-difluoro-2H-bite dilute-3-carboxylic acid (1.0 part by weight) in propylene (1 〇.〇 volume) and triethylamine (〇71 parts by volume, 丨〇 9 molar equivalents of the solution. The reaction mixture was then monitored by HPLC until the reaction was complete. The reaction mixture was then diluted with cold water (20.0 parts by volume) to allow the intermediate azide to "cool the suspension to < 1 〇 ° C and kept at <丨〇.〇 for 1,0 h. Then the suspension is filtered and then water 5 parts by volume) Washing. The aqueous wet matter is then taken up in di-methane (7.5 parts by volume) and separated from each phase by 135964.doc -34-200927740. The resulting two-gas calcination solution is dried using sulfuric acid. At 60 ° C, the W addition rate is equal to the collection of the museum (4), the dichloromethane azide solution is added to methanol (60 parts by volume). Once added, continue to distill until the top temperature of the distillation tower reaches 60 Then, the system was set to reflux. The reaction was then monitored by HPLC until the reaction was completed. The reaction mixture was then cooled to <15 ° C and concentrated under vacuum to a volume of 2 parts, followed by di-methane ( The crude reaction mixture was diluted with 7.5 parts by volume and heptane (2.5 parts by volume), then dihydromethane was distilled at atmospheric pressure, and the reaction mixture was concentrated to 6.0 parts of volume. After cooling to 25 ° C, petroleum ether was slowly added. (10 0 parts by volume) to crystallize the title compound. After complete addition, the resulting suspension was cooled to < 5 ° C and maintained at 5 ° C for 1.0 h. The title compound was then filtered and then petroleum ether (5.0 parts by volume) Polyester then dried in vacuo at 35 ° C the product of strange given weight is to be understood that the invention may be modified within the scope of the patent application in the scope of the appended claims.

135964.doc •35·135964.doc •35·

Claims (1)

200927740 十、申請專利範圍: 1. 一種製備式B化合物之方法,200927740 X. Patent application scope: 1. A method for preparing a compound of formula B, B V' 0 該方法包括將式VII化合物B V' 0 The method comprises the compound of formula VII 轉化成s亥式B化合物,其中R!、R2及R3為相同或不同且 表示氫、豳素、烷基、烷基氧基、羥基、硝基、烷基羰 基胺基、烷基胺基或二烷基胺基;尺4為烷基或芳基;且 R5為·Ν3或-NH2 ’其中:術語烷基意謂直鏈或支鍵、含 有一至六個碳原子、視情況經芳基、烷氧基、鹵素、烷 氧羰基或羥基羰基取代之烴鏈;術語芳基意謂視情況經 烷基氧基、齒素或硝基取代之苯基或萘基;且術語鹵素 意謂氟、氣、溴或碘。 2·如請求項1之方法’其中及R3之至少-者為氟。 3.如請求項1或2之方法,其中R4為c】至c4院基。 用求項1、2或3之方法,其中R4為曱基、乙基或第三 丁基。 5_如則述請求項中任—頂:^古'土 ^ . $甲任項之方法,其中R4為甲基。 6·如:求項1或2之方法’其中I為节基。 7·如剛返請求項中任一項之方法,其中化合物Μ具有式工 135964.doc 200927740Converted to a compound of the formula B, wherein R!, R2 and R3 are the same or different and represent hydrogen, halogen, alkyl, alkyloxy, hydroxy, nitro, alkylcarbonylamino, alkylamino or a dialkylamine group; the rule 4 is an alkyl group or an aryl group; and R5 is ·Ν3 or -NH2 ' wherein: the term alkyl means straight or branched, containing one to six carbon atoms, optionally an aryl group, a hydrocarbon chain substituted with an alkoxy group, a halogen, an alkoxycarbonyl group or a hydroxycarbonyl group; the term aryl means a phenyl or naphthyl group optionally substituted with an alkyloxy group, a dentate or a nitro group; and the term halogen means fluorine, Gas, bromine or iodine. 2. The method of claim 1 wherein at least R3 is fluorine. 3. The method of claim 1 or 2, wherein R4 is c] to c4. The method of claim 1, 2 or 3 wherein R4 is a decyl group, an ethyl group or a tert-butyl group. 5_If the claim item is any - top: ^古 '土 ^. $ A method of any of the items, wherein R4 is a methyl group. 6. The method of claim 1 or 2 wherein I is a node. 7. The method of any of the preceding claims, wherein the compound has a formula 135964.doc 200927740 8.如請求項1之方法 其中化合物VII具有式IA8. The method of claim 1 wherein compound VII has formula IA IA。 9_如請求項1至6中任一項之方法 其中化合物VII具有式VIA. 9_ The method of any one of claims 1 to 6, wherein the compound VII has the formula V 1〇.如請求項1之方法’其中化合物νπ具有式VA1. The method of claim 1, wherein the compound νπ has the formula VA 11 ·如前述請求項中任一項之方法 反應。 其中該轉化法包括重組 12.如5青求項, 4之方法 其中該轉化法包括霍夫曼 (Hoffman)重組反應。 1 3.如請求項9戎丨0夕古、车,丄 - 方法其中該轉化法包括庫爾提斯 (Curtius)重組 β 14.如叫求項7、8或12之方法’其中該轉化法包括在次鹵酸 -及式R4〇H之醇(其中r4具有如請求項1Α3至6中任一項 中所、.σ出之相同意義)存在下,使酿胺基團重組形成胺基 135964.doc 200927740 甲酸酯基團。 忐舱項Η之方法’其中R4為甲基且該轉化法包括在 鈉及甲醇存在下進行重組反應。 15. 次 16.如請求項9、1〇或13 ,T/f 飞3之方去,其中該重組反應包括將該 式1化合物溶於該醇中,添加該次齒酸鹽且維持該反應物 之溫度低於l〇°C。 其中該次#酸鹽為次氣酸 17.如請求項14、15或16之方法, 鹽。 ❹ 8·如引述6月求項中任—項之方法,其中該式B化合物係藉 由再結晶純化。 月求項18之方法,其中該再結晶法係在水/2_丙醇混合 物中進行。 20.如請求項7或附屬於請求項7之任一項之方法其中該式I 化合物製法係由式Π化合物11. A method of reacting according to any of the preceding claims. Wherein the transformation method comprises recombination 12. The method of 4, wherein the transformation method comprises a Hoffman recombination reaction. 1 3. The method of claim 9 戎丨 夕 、 、, 车, 丄 - method, wherein the conversion method includes Curtius recombination β 14. The method of claim 7, 8, or 12 In the presence of a hypohalous acid-and an alcohol of the formula R4〇H (wherein r4 has the same meaning as defined in any one of claims 1 to 3 to 6), the amine group is recombined to form an amine group 135964 .doc 200927740 Formate group. The method of the present invention wherein R4 is a methyl group and the conversion method comprises a recombination reaction in the presence of sodium and methanol. 15. Times 16. In the case of claim 9, 〇 or 13 , the T/f fly 3 is removed, wherein the recombination reaction comprises dissolving the compound of formula 1 in the alcohol, adding the dentate salt and maintaining the reaction. The temperature of the object is below l〇 °C. Wherein the #acid salt is a sub-gas acid. 17. The method of claim 14, 15 or 16, salt. ❹ 8. The method of any of the items of the sixth aspect of the present invention, wherein the compound of the formula B is purified by recrystallization. The method of claim 18, wherein the recrystallization method is carried out in a water/2-propanol mixture. 20. The method of claim 7, or the method of any one of claim 7, wherein the compound of formula I is produced from a compound of formula 轉化成該式I化合物,其中Rl、心及!^具有與化合物 相同之意義。 21.如請求項2〇之方法,其中該式π化合物具有式ΠΑConversion to a compound of formula I wherein R1, heart and !^ have the same meaning as the compound. 21. The method of claim 2, wherein the compound of formula π has the formula F F 22·如請求項20或21之方法,其中該II形成I之轉化法包括在 酸存在下水解。 135964.doc 200927740 23.如請求項22之方法,其中該酸為無機酸及有機酸 24·如請求項23之方法,其中該有機醆為乙酸。 25. 如請求項23或24之方法,其中該無機酸為硫酸。 26. 如請求項21之方法,其中該式b化合物具有下式F F 22. The method of claim 20 or 21, wherein the method of converting the II to I comprises hydrolyzing in the presence of an acid. The method of claim 22, wherein the acid is a mineral acid and an organic acid. The method of claim 23, wherein the organic hydrazine is acetic acid. 25. The method of claim 23 or 24 wherein the mineral acid is sulfuric acid. 26. The method of claim 21, wherein the compound of formula b has the formula 27.如請求項9、llstl3之方法’其中由¥形成b之轉化法包 括在具有式R4〇H之醇(其中&amp;具有如請求項3至6中任一 項所給出之相同意義)存在下進行熱分解。 28·如請求項27之方法’其中該熱分解法包括將該式v化合27. The method of claim 9, llstl3 wherein the conversion method of forming b from ¥ is included in an alcohol having the formula R4〇H (where &amp; has the same meaning as given in any one of claims 3 to 6) Thermal decomposition is carried out in the presence. 28. The method of claim 27, wherein the thermal decomposition method comprises combining the formula v 且製備該式B化合物之方法包括以下步驟.And the method for preparing the compound of the formula B comprises the following steps. 物溶於有機溶劑,及將該反應混合物加熱至該有機溶劑 之回流溫度。 29.如請求項28之方法,其中該有機溶劑為二氣甲烷、甲苯 或乙酸乙酯。 3 0.如睛求項27、28或29之方法,其中該具有sR4〇H之醇為 該有機溶劑。 31·如請求項28、29或30之方法,其中將該式v化合物溶於 該有機溶劑之過程係在5(rc至7(rc範圍内之溫度下進 行。 135964.doc 200927740 32·如請求項31之方法’其中將該式v化合物溶於該有機溶 劑之過程係在35°C至8(TC範圍内之溫度下進行。 33. 如請求項32之方法’其中將該式μ合物溶於該有機溶 劑之過程係在約60°C之溫度下進行。 34. 如請求項27至33中任一項之方法,其中在反應完成後, 將該反應混合物冷卻,視情況濃縮且添加第二溶劑以使 該式B化合物結晶。 35. 如請求項34之方法,其中該第二溶劑為選自石油醚、己 炫*、或庚烧之有機溶劑。 36. 如請求項34之方法,其中該第一有機溶劑為可與水混溶 之溶劑且該第二溶劑為水。 37·如請求項34、35或36之方法,其中該冷卻法係達3〇。〇以 下’較佳係151以下之溫度。 38.如請求項27至37中任一項之方法,其中該式μ合物製 法係藉由將式VI化合物The material is dissolved in an organic solvent, and the reaction mixture is heated to the reflux temperature of the organic solvent. 29. The method of claim 28, wherein the organic solvent is di-methane, toluene or ethyl acetate. The method of claim 27, 28 or 29, wherein the alcohol having sR4〇H is the organic solvent. The method of claim 28, 29 or 30, wherein the process of dissolving the compound of the formula v in the organic solvent is carried out at a temperature of 5 (rc to 7 (rc range). 135964.doc 200927740 32. The method of the item 31, wherein the process of dissolving the compound of the formula v in the organic solvent is carried out at a temperature in the range of from 35 ° C to 8 (the range of TC. 33. The method of claim 32, wherein the compound of the formula The process of dissolving in the organic solvent is carried out at a temperature of about 60 ° C. The method of any one of claims 27 to 33, wherein after the reaction is completed, the reaction mixture is cooled, optionally concentrated and added The second solvent is used to crystallize the compound of the formula B. 35. The method of claim 34, wherein the second solvent is an organic solvent selected from the group consisting of petroleum ether, hexahydrogen, or heptane. 36. The method of claim 34 Wherein the first organic solvent is a water-miscible solvent and the second solvent is water. 37. The method of claim 34, 35 or 36, wherein the cooling method is up to 3 Torr. The method of any one of claims 27 to 37, wherein the method of any one of claims 27 to 37, wherein A compound of formula μ law prepared by the compound of formula VI ΟΟ 轉化成該式ν化合物,其中Ri、R2&amp;R3具有與化合物乂中 相同之意義。 39.如請求項38之方法,其中該式…化合物具有下式 135964.doc 200927740 40·如請求項38或39之方法,其中該¥1形成v之轉化法包括 使用醯基疊氮化物形成劑。 41. 如請求項38、39或40之方法,其中該¥1形成丫之轉化法 係在可與水混溶之溶劑存在下進行。 42. 如請求項41之方法,其中該可與水混溶之溶劑為丙酮、 乙腈、DMF、THF、二噁烷或1,2-二甲氧基乙烷。 43. 如請求項38至42中任一項之方法,其中該丨形成v之轉 化法係在鹼存在下進行。 ^ 44.如請求項40之方法,其中該醯基疊氮化物形成劑為二笨 基磷醯基疊氮化物且該轉化法係在鹼存在下進行。 45. 如請求項43或44之方法,其中該鹼為三乙基胺、三丙基 胺或三丁基胺。 46. 如請求項38至45中任一項之方法,其中藉由向反應混合 物添加冷水’使該式V化合物自其中沈澱。 47_如請求項46之方法,其中將該式v化合物之懸浮液冷 • 卻、過濾且以適合之有機溶劑萃取濕濾餅。 48.如請求項38至47中任一項之方法,其中該式¥1化合物製 法係由式II化合物Conversion to a compound of the formula ν wherein Ri, R2 &amp; R3 have the same meaning as in the oxime of the compound. 39. The method of claim 38, wherein the compound of the formula has the formula 135964.doc 200927740 40. The method of claim 38 or 39, wherein the conversion of the ¥1 formation v comprises the use of a sulfhydryl azide former . 41. The method of claim 38, 39 or 40, wherein the conversion of the hydrazine forming the hydrazine is carried out in the presence of a water miscible solvent. 42. The method of claim 41, wherein the water miscible solvent is acetone, acetonitrile, DMF, THF, dioxane or 1,2-dimethoxyethane. The method of any one of claims 38 to 42, wherein the conversion of the oxime to v is carried out in the presence of a base. 44. The method of claim 40, wherein the sulfhydryl azide forming agent is a diphenylphosphonium azide and the conversion is carried out in the presence of a base. 45. The method of claim 43 or 44, wherein the base is triethylamine, tripropylamine or tributylamine. The method of any one of claims 38 to 45, wherein the compound of formula V is precipitated therefrom by adding cold water to the reaction mixture. 47. The method of claim 46, wherein the suspension of the compound of formula v is cooled, filtered, and the wet cake is extracted with a suitable organic solvent. The method of any one of claims 38 to 47, wherein the compound of the formula 1 is a compound of formula II N II 轉化成該式VI化合物,其中Rl、R2及R3具有與化合物νι 中相同之意義。 49.如請求項48,方法,其中該式Π化合物具有下式 135964.doc -6- 200927740N II is converted to the compound of formula VI wherein R1, R2 and R3 have the same meaning as in compound νι. 49. The method of claim 48, wherein the compound of the formula has the formula 135964.doc -6- 200927740 50. 如請求項48或49之方法,其中制形成νι之轉化法包括 使該式II化合物上之腈部分基團水解。 51. 如凊求項5〇之方法,其中該水解法包括使該式I〗化合物 與驗在水存在下反應,隨後以酸處理。 52. 如請求項51之方法,其中該鹼為氫氧化鈉、氫氧化鋰或 ❾ 氫氧化_。 53. 如叫求項51或52之方法,其中該酸為鹽酸、硫酸或磷 酸。 54. 如請求項20至26或48至53中任一項之方法,其中該式π 化合物製法係由式III化合物50. The method of claim 48 or 49, wherein the converting to form a νι group comprises hydrolyzing a nitrile moiety on the compound of formula II. 51. The method of claim 5, wherein the hydrolysis comprises reacting the compound of formula I with a test in the presence of water followed by treatment with an acid. 52. The method of claim 51, wherein the base is sodium hydroxide, lithium hydroxide or cesium hydroxide. 53. The method of claim 51 or 52, wherein the acid is hydrochloric acid, sulfuric acid or phosphoric acid. The method of any one of claims 20 to 26 or 48 to 53, wherein the method of formulating the compound of formula π is a compound of formula III ❿ 轉化成該式II化合物,其中I、R2及R3具有與化合物„ 中相同之意義。 55.如請求項54之方法,其中該式ΙΠ化合物具有式ΙΠΑ❿ is converted to the compound of the formula II, wherein I, R2 and R3 have the same meanings as in the compound „. 55. The method of claim 54, wherein the hydrazine compound has the formula ΙΠΑ 56.如請求項54或55之方法,其中該III形成π之轉化法包括 環化縮合反應。 135964.doc 200927740 A如請求項54、55或56之方法,其中該卿成π之轉化法 係在丙稀腈及Μ_重氮雙環[2.2.2]辛烧存在下進行。 认如請求項54至57中任—項之方法’其中將該反應混合物 加熱至5〇°c至9CTC範圍内之溫度。 59.如吻求項58之方法,其中將該反應混合物加熱至赃至 80 C範圍内之溫度。 6〇.如請求項59之方法,其中將該反應混合物加熱至約贼 之溫度。 如凊求項54至60中任一項之方法,其中該反應係在溶劑 中進行》 62·如請求項61之方法,其中該溶劑為純丙烯腈。 63.如請求項61之方法,其中該溶劑為dmf。 64·如叫求項54至63中任一項之方法其中該式出化合物製 法係由式IV化合物56. The method of claim 54 or 55, wherein the conversion of the III to π comprises a cyclization condensation reaction. 135964.doc 200927740 A. The method of claim 54, 55 or 56, wherein the conversion to π is carried out in the presence of acrylonitrile and hydrazine-diazabicyclo[2.2.2] octane. The method of any one of claims 54 to 57 wherein the reaction mixture is heated to a temperature in the range of 5 ° C to 9 CTC. 59. The method of claim 58, wherein the reaction mixture is heated to a temperature in the range of 赃 to 80 C. The method of claim 59, wherein the reaction mixture is heated to a temperature of about thief. The method of any one of items 54 to 60, wherein the reaction is carried out in a solvent. The method of claim 61, wherein the solvent is pure acrylonitrile. 63. The method of claim 61, wherein the solvent is dmf. 64. The method of any one of claims 54 to 63 wherein the compound is produced from a compound of formula IV 中相同之意義。 65.如請求項64之方法,其中該式…化合物具有下式 轉化成該式III化合物,其中 IV OHRi、R2及R3具有與化合物inThe same meaning in the middle. 65. The method of claim 64, wherein the compound of the formula has the formula: wherein the IV OHRi, R2 and R3 have a compound in 66.如请求項64或65之方法,其中該IV形成III之轉化法包括 135964.doc 200927740 使該式ιν化合物與甲醯化劑反應。 .67.如請求項66之方法,其中該甲酿化劑為六亞甲基四胺。 68. 如請求項66或67之方法,其中該轉化法係在酸存在下進 行。 69. 如請求項68之方法,其中該酸為三氟乙酸。 70. 如請求項66至69中任一項之方法,其中在添加該曱醯化 •劑之後,將該反應混合物之溫度升高至6〇°C至1〇〇。(:範圍 内之溫度。 71. 如請求項70之方法’其中將該反應混合物之溫度升高至 70°C至90。〇範圍内之溫度。 72. 如請求項71之方法,其中將該反應混合物之溫度升高至 約80°C之溫度。 73. 如請求項70至72中任一項之方法,其中將該升高之溫度 維持至少60分鐘之時間。 74. 如叫求項73之方法,其中在維持該升高之溫度後,將該 〇 反應混合物之溫度進一步升高至約90°C至約13(TC範圍内 之溫度。 75. 如請求項74之方法,其中將該反應混合物之溫度進一步 升高至約WOt至約12(TC範圍内之溫度。 76. 如請求項75之方法,其中將該反應混合物之溫度進一步 升高至約11 5。(:之溫度。 ” ·如請求項71至对任—項之方法,其中將該反應物冷卻 至約lot至約45t範圍内之溫度。 78.如請求項77之方法’其中將該反應物冷卻至㈣。〇至約 135964.doc 200927740 35°c範圍内之溫度。 79.如請求項78之方法,其中將該反應物冷卻至約30°C之溫 度。 8〇·如請求項64至79中任一項之方法,其中在反應完成後, 添加水,形成懸浮液。 8 1 ·如請求項8〇之方法,其中過濾該懸浮液且再以水洗滌。 82.如請求項64之方法,其中該式b化合物具有下式66. The method of claim 64 or 65, wherein the method of converting the IV to form III comprises 135964.doc 200927740 reacting the compound of formula iv with a formazaming agent. The method of claim 66, wherein the brewing agent is hexamethylenetetramine. 68. The method of claim 66 or 67, wherein the transformation is carried out in the presence of an acid. 69. The method of claim 68, wherein the acid is trifluoroacetic acid. The method of any one of claims 66 to 69, wherein the temperature of the reaction mixture is raised to 6 ° C to 1 Torr after the addition of the oximation agent. (The temperature in the range. 71. The method of claim 70, wherein the temperature of the reaction mixture is raised to a temperature in the range of from 70 ° C to 90 °. 72. The method of claim 71, wherein The temperature of the reaction mixture is raised to a temperature of about 80 ° C. The method of any one of claims 70 to 72, wherein the elevated temperature is maintained for a period of at least 60 minutes. The method of claim 74, wherein the temperature of the hydrazine reaction mixture is further increased to a temperature in the range of from about 90 ° C to about 13 (the range of TC. 75. The method of claim 74, wherein The temperature of the reaction mixture is further increased to a temperature in the range of from about WOt to about 12 (the range of TC. 76. The method of claim 75, wherein the temperature of the reaction mixture is further increased to about 11 5. (: temperature.) The method of claim 71 to the above, wherein the reactant is cooled to a temperature in the range of from about lit to about 45. 78. The method of claim 77, wherein the reactant is cooled to (d). Approximately 135964.doc 200927740 Temperature in the range of 35 ° c. 79 The method of claim 78, wherein the reaction is cooled to a temperature of about 30 ° C. The method of any one of claims 64 to 79, wherein after the reaction is completed, water is added to form a suspension. 8. The method of claim 8 wherein the suspension is filtered and washed with water. 82. The method of claim 64, wherein the compound of formula b has the formula e F NHC02Me 且製備該式B化合物之方法包括以下步驟:e F NHC02Me and the method of preparing the compound of formula B includes the following steps: 如請求項64之方法,其中該式B化合物具有下式The method of claim 64, wherein the compound of formula B has the formula 且製備該式B化合物之方法包括以下步驟: 135964.doc •10- 200927740And the method for preparing the compound of the formula B comprises the following steps: 135964.doc •10- 200927740 NN 84.如前述請求項中任一項之方法,其中將該式b化合物轉 化成式A化合物之s或R對映異構體, ❹The method of any of the preceding claims, wherein the compound of formula b is converted to the s or R enantiomer of the compound of formula A, A 其中R!、R2、R3、R4具有如請求項i至6中任一項所給出 之相同意義。 85.如請求項84之方法,其中化合物八具有下式:A wherein R!, R2, R3, R4 have the same meaning as given in any one of claims i to 6. 85. The method of claim 84, wherein compound VIII has the formula: 86. 如請求項84或85之方法,其 丹1PR*為C丨至C4烷基。 87. 如請求項86之方法,其中〜為 吞'、乙基或tBu 88. 如請求項87之方法,其中R4為甲基。 89. 如請求項84或85之方法, 丹TI為节基。 90. 如請求項84至89中任一項之方法 土 映異構體形式。 4 ,其中化合物A係呈8對 91. 如請求項84至89中任一項之方 、,其中化合物A係呈R對 135964.doc 200927740 映異構體形式。 92. 如請求項84至91中任一項之方法’其中該方法進一步包 括含將該化合物Α之R或S對映異構體轉化成式C化合物 或其鹽之相應R或S對映異構體,86. The method of claim 84 or 85, wherein the 1PR* is C丨 to C4 alkyl. 87. The method of claim 86, wherein ~ is enthalpy, ethyl or tBu. 88. The method of claim 87, wherein R4 is methyl. 89. As requested in item 84 or 85, Dan TI is the basis. 90. The method of any one of claims 84 to 89, which is in the form of an enantiomer. 4, wherein the compound A is in the form of a pair of 91. 91. The compound A is in the form of R to 135964.doc 200927740. The method of any one of claims 84 to 91 wherein the method further comprises converting the R or S enantiomer of the compound oxime to the corresponding R or S pair of the compound of formula C or a salt thereof Structure, 其中Ri、R2及R3為相同或不同且表示氫、鹵素、烧基、 烧基氧基、羥基、硝基、烷基羰基胺基、烷基胺基或二 烧基胺基’其中:術語烷基意謂直鏈或支鏈、含有一至 六個碳原子、視情況經芳基、炫氧基、鹵素、院氧羰基 或羥基羰基取代之烴鏈;且術語函素意謂氟、氣、漠或 礎。 93. 94. 如請求項92之方法,其中將該式C化合物或其鹽之尺或^ 對映異構體轉化成式E化合物或其鹽之相應R或S對映異 構體,Wherein Ri, R2 and R3 are the same or different and represent hydrogen, halogen, alkyl, alkyloxy, hydroxy, nitro, alkylcarbonylamino, alkylamino or dialkylamino' wherein: the term alkane The meaning of a straight or branched chain hydrocarbon chain containing one to six carbon atoms, optionally substituted with an aryl group, a methoxy group, a halogen, a oxycarbonyl group or a hydroxycarbonyl group; and the term nuclide means fluorine, gas, and desert Or foundation. 94. The method of claim 92, wherein the compound of formula C or a salt or an enantiomer thereof is converted to the corresponding R or S enantiomer of a compound of formula E or a salt thereof, ❹ 其中Rl2表示氫、炫基或烧基芳基;且!^為1、2或3。 如請求項93之方法,其中使該式c化合物之R或S對映異 構體與式D2化合物 135964.doc • 12- 200927740❹ wherein Rl2 represents hydrogen, thio or aryl aryl; and !^ is 1, 2 or 3. The method of claim 93, wherein the R or S enantiomer of the compound of formula c is compared to the compound of formula D 135964.doc • 12-200927740 與水溶性硫氰酸鹽,在有機酸存在下,在實質上惰性溶 劑中反應’隨後脫除中間產物F至I之保護基:Reacting with a water-soluble thiocyanate in the presence of an organic acid in a substantially inert solvent. Subsequent removal of the protecting group of intermediates F to I: F G nr12r13 ❹F G nr12r13 ❹ 從而生成式E化合物或其鹽之相應R或S對映異構體,Thereby producing the corresponding R or S enantiomer of the compound of formula E or a salt thereof, 其中η表示1、2或3 ; R】2表示氫、烷基或烷基芳基, . KH 表不羥基保護基且Ru表示胺基保護基,或Rll係如 、·^上文 所定義但R12與R13—起表示酞醯亞胺基。 95.如請求項94之方法’其中該水溶性硫氰酸鹽為鹼金屬破 氰酸鹽或硫氰酸四烷基銨。 135964.doc 13 200927740 96.如:束項94或95之方法,其中該溶劑為有機溶劑β 如青求項94至96中任一項之方法,纟中該式Ε化合物為 ()(2胺基乙基)-1 _咬咬-3-基_ 1,3_二氬ρ米吐-2-硫網; ()(2~胺基乙基)-1-(6_經基咬&lt;»完_3•基)-1,3-二氫咪唑-2· 硫酮;(R)-5-(2-胺基乙基卜丨-“—羥基咣嘀_3_基)_i,3-二氫 咪坐2-硫_ ;(尺)_5_(2_胺基乙基)_ι_(6_甲氧基咣啶_3· 基)-1,3-二氫咪唑·2_硫酮;(11)_5_(2_胺基乙基卜卜”甲氧 基咣咣-3-基)_ι,3·二氫咪唑_2·硫酮;(R)_5彳2_胺基乙基)_ 1- (6-氟咣啶-3-基)-i,3-二氫咪唑_2_硫酮;(R)_5_(2·胺基 乙基)-1-(8-氟咣咣-3-基)-1,3-二氩咪唑_2_硫酮;(R)-5-(2-胺基乙基)-1-(6,7-二氟咣咣-3-基)-i,3-二氫咪唑-2-硫酮; (R)-5-(2-胺基乙基)-1-(6,8-二氟咣咣·3_基)-1,3-二氫咪唑- 2- 硫_,(S)-5-(2-胺基乙基)-1_(6,8_二氟 u克喷-3-基)-1,3_ 二氫咪唑-2-硫酮;(R)-5-(2-胺基乙基)-1-(6,7,8-三氟咣 咣-3-基)-1,3-二氫咪唑-2-硫酮;(R)-5-(2-胺基乙基)·1-(6-氣-8-甲氧基咣嘀-3-基)-1,3-二氫咪唑-2-硫酮;(R)-5-(2-胺基乙基)-1-(6-甲氧基-8-氣咬咬-3-基)-1,3-二氫咪°坐-2-硫嗣;(R)_5- (2 -胺基乙基)-1-(6 -硝基咬0完-3 -基)-1,3-二 氫咪唑-2-硫酮;(R)-5-(2-胺基乙基)-1-(8-硝基咣啶-3-基)-1,3-二氫咪唑-2-硫酮;(R)-5-(2-胺基乙基)-1-[6-(乙 醯基胺基)咣11 完-3-基]-1,3·二氫咪唑_2_硫酮;(R)-5-胺基 曱基克咬-3-基-1,3-二氫味吐-2-硫酮;(R)-5-胺基曱 基_1_(6-經基p克咬基)-1,3-二氫咪唾-2-硫嗣,(R)-5-(2-胺基乙基)-1-(6 -經基-7-节基咬°完-3 -基),1,3 -—氣味°坐-2- 135964.doc -14- 200927740 度嗣,(R)'5'胺基甲基-1-(6,8-二氟咬喷-3-基)-l,3-二氣味 爪綱’(r)_5_(3_胺基丙基)·ι_(6,8_二氟tr克ντ完·3_基卜 H一風味唾硫酮;(R) 5 (2苄基胺基乙基)“·⑸曱 氧基咣咣基)-丨,3-二氫咪唑-2-硫酮;(R)-5-(2-苄基脸 .土 ·κ(6-羥基咣咣-3-基)-1,3_二氫咪唑-2-硫酮; 1 (^沒基'完-3-基)_5·(2_甲基胺基乙基)-1,3-二氫咪0坐_ 2瓜酮,氟咣啶_3_基)_5_(2_甲基胺基乙基)、 ❹ I’3 一氫咪唑-2_硫酮或(R)-l-咣咣-3-基-5-(2-甲基胺基乙 基)-1,3_二氫咪唑-2-硫酮。 98.如請求項94至96中任-項之方法,其中該式E化合物為 化合物之鹽:(R)_5-(2'胺基乙基)_1_咣咣_3_基_1,3-一氯米唾-2-硫酮;(R)-5-(2-胺基乙基)-1-(6-經基t完-3-基)1’3-一氫咪唑_2_硫_ ; 胺基乙基)-ΐ-(8·羥基 克το 3-基^^,弘二氫咪唑_2•硫酮;(R)_5_(2_胺基乙基卜卜 (6·曱氧基吱喷_3_基)]}二氣味吐_2·硫酮;⑻_5_(2_胺 〇 基乙基)-1-(8-甲氧基咣啶_3-基)_丨,3_二氫咪唑-2-硫酮; (R)-5-(2-胺基乙基)_i_(6_氟吮啶_3基卜丨,%二氫咪唑_2•硫 綱;(R)-5-(2-胺基乙基)七(8_氟咣咣_3基w,%二氫咪 唑-2-硫酮;(R)_5-(2-胺基乙基卜卜^^二氟咣咣_3_基)_ I,3-二氫咪唑_2_硫酮;(R)_5_(2_胺基乙基)二氟咣 °凡-3-基)-1,3-二氫咪唑-2-硫酮;(8)_5_(2_胺基乙基)_1_ (6,8-二氟咣嗖-3-基)-1,3-二氫咪唑_2_硫酮;(11)_5_(2_胺 基乙基)-1-(6,7,8-二氟'1克咬_3_基)_1,3_二氫咪嗤_2_硫酮; (R)-5-(2-胺基乙基)-1-(6-氣曱氧基咣嘀_3_基二氫 135964.doc * 15 - 200927740 咪唑-2-硫酮;(R)-5-(2-胺基乙基)-卜(6-甲氧基-8-氣咣啶-3-基)-1,3-二氫味嗤-2-硫酮;(R)-5-(2-胺基乙基)-1-(6-石肖 基咣啶-3-基)-1,3-二氫咪唑-2-硫酮;(R)-5-(2-胺基乙基)- 1- 0硝基咣咣-3-基)-1,3-二氫咪唑-2-硫酮;(R)-5-(2-胺 基乙基)-1_[6-(乙醯基胺基)咣啶-3-基]-1,3·二氫咪唑-2- « 硫酮;(R)-5-胺基甲基-1-咣啶-3-基-1,3-二氫咪唑-2-硫 •酮;(R)-5-胺基甲基-1-(6-羥基咣咣-3-基)-1,3-二氫咪唑- 2- 硫_ ; (R)_5-(2-胺基乙基)-1-(6-羥基-7-苄基咣啶-3-基)-1,3-二氫咪唑·2·硫酮;(R)-5-胺基甲基-1-(6,8-二氟p克 咬-3-基)-1,3-二氫咪唑-2-硫酮;(R)-5-(3-胺基丙基)-1-(6,8-—氟 p克咬-3-基)-1,3-二氫味 &lt;»坐-2-硫酮;(R)-5-(2-节 基胺基乙基)-1-(6-甲氧基咣啶-3-基)-1,3-二氩咪唑-2-硫 酮;(R)-5-(2·苄基胺基乙基)·1-(6-羥基咣《完-3-基)-1,3-二 氫味唾-2-硫酮;(R)-l-(6-羥基咣嘀-3-基)-5-(2-甲基胺基 乙基)-1,3-二氫咪唑-2-硫輞;(R)_i_(6,8-二氟咣咣-3-基)- φ 5_(2_甲基胺基乙基)·1,3-二氫咪嗤-2-硫酮或(R)-l-p克喷- 3- 基-5-(2-甲基胺基乙基)-1,3-二氫咪唾_2_琉酮。 99,如請求項98之方法,其中該鹽為鹽酸鹽。 , 100.如請求項94至95中任一項之方法,其中該式e化合物為 ,式P化合物之R或S對映異構體。Wherein η represents 1, 2 or 3; R] 2 represents hydrogen, alkyl or alkylaryl, . . . KH represents a hydroxy protecting group and Ru represents an amine protecting group, or R ll is as defined above, R12 and R13 together represent a quinone imine group. 95. The method of claim 94 wherein the water soluble thiocyanate is an alkali metal cyanide or a tetraalkylammonium thiocyanate. </ RTI> </ RTI> </ RTI> </ RTI> </ RTI> </ RTI> </ RTI> </ RTI> </ RTI> </ RTI> </ RTI> </ RTI> </ RTI> </ RTI> </ RTI> </ RTI> </ RTI> </ RTI> <RTIgt; Base ethyl)-1 _ bite-3-yl_ 1,3_di-argon ρ-methane-2-sulfur mesh; ()(2~aminoethyl)-1-(6_base-bite &lt;»End_3•yl)-1,3-dihydroimidazole-2·thione; (R)-5-(2-aminoethyldipyridyl-“-hydroxyindole_3_yl)_i,3 - dihydromilyl sitting 2-sulfo _; (foot) _5_(2_aminoethyl)_ι_(6-methoxyacridine_3·yl)-1,3-dihydroimidazole·2-thione; (11) _5_(2_Aminoethylbub) methoxyindol-3-yl)_ι,3·dihydroimidazole_2·thione; (R)_5彳2_aminoethyl) 1-(6-fluoroacridin-3-yl)-i,3-dihydroimidazole-2-thione; (R)_5_(2·aminoethyl)-1-(8-fluoroindole-3 -yl)-1,3-di-argonimide-2-thione; (R)-5-(2-aminoethyl)-1-(6,7-difluoroindol-3-yl)-i , 3-dihydroimidazole-2-thione; (R)-5-(2-aminoethyl)-1-(6,8-difluoroindole-3-yl)-1,3-dihydrogen Imidazole 2- 2-sulfo-, (S)-5-(2-aminoethyl)-1_(6,8-difluoro-u-pent-3-yl)-1,3_ Imidazole-2-thione; (R)-5-(2-aminoethyl)-1-(6,7,8-trifluoroindol-3-yl)-1,3-dihydroimidazole-2 -thione; (R)-5-(2-aminoethyl)·1-(6-gas-8-methoxyindol-3-yl)-1,3-dihydroimidazole-2-sulfur Ketone; (R)-5-(2-aminoethyl)-1-(6-methoxy-8-gasbiti-3-yl)-1,3-dihydromethane (R)_5-(2-Aminoethyl)-1-(6-nitrobite-end-3-yl)-1,3-dihydroimidazole-2-thione; (R)-5 -(2-Aminoethyl)-1-(8-nitroacridin-3-yl)-1,3-dihydroimidazole-2-thione; (R)-5-(2-Amino B Base)-1-[6-(ethinylamino)phosphonium 11 -3-yl]-1,3·dihydroimidazole-2-thione; (R)-5-aminoindenyl ketone- 3-yl-1,3-dihydro-sodium-2-thione; (R)-5-aminoindolyl-1_(6-radio-p-butyl)-1,3-dihydropropanoid- 2-thioindole, (R)-5-(2-aminoethyl)-1-(6-trans-yl-7-nodal bite-end-3-yl), 1,3 -- odor ° sitting- 2- 135964.doc -14- 200927740 degree 嗣, (R) '5' aminomethyl-1-(6,8-difluorocarbazone-3-yl)-l,3-diodoric claw class' r)_5_(3_Aminopropyl)·ι_(6,8_Difluorotrkντ完·3_基卜H-flavored salium (R) 5 (2-benzylaminoethyl) "·(5) fluorenyl fluorenyl)-indole, 3-dihydroimidazole-2-thione; (R)-5-(2-benzyl face .·············· Ethyl)-1,3-dihydromethane 0 sitting _ 2 melon ketone, fluoroacridine _3_yl)_5_(2_methylaminoethyl), ❹ I'3 monohydroimidazole-2 thiol Or (R)-l-indol-3-yl-5-(2-methylaminoethyl)-1,3-dihydroimidazole-2-thione. The method of any one of claims 94 to 96, wherein the compound of the formula E is a salt of the compound: (R)_5-(2'aminoethyl)_1_咣咣_3_yl_1,3 -monochloromethane-2-thione; (R)-5-(2-aminoethyl)-1-(6-carbyl t--3-yl) 1'3-monohydroimidazole_2 Sulfur _; Aminoethyl)-indole-(8.hydroxyl το 3-yl^^, hongdihydroimidazole_2•thione; (R)_5_(2_Aminoethylbub (6·曱Oxygen) Base 吱 _3_ base)]} two odor spit _2 thioketone; (8) _5_(2_Aminomethyl)-1-(8-methoxyacridine-3-yl) 丨, 3_ Dihydroimidazole-2-thione; (R)-5-(2-Aminoethyl)_i_(6-fluoroacridine_3 hydrazin, % dihydroimidazole _2 thiol; (R)- 5-(2-Aminoethyl)-7 (8-fluoroindole-3-yl, w,% dihydroimidazole-2-thione; (R)_5-(2-Aminoethylbub^^difluoro咣咣_3_yl)_ I,3-dihydroimidazole-2-thione; (R)_5_(2-aminoethyl)difluoroanthracepin-3-yl)-1,3-dihydrogen Imidazole-2-thione; (8) _5_(2-aminoethyl)_1_(6,8-difluoroindol-3-yl)-1,3-dihydroimidazole-2-thione; (11 )_5_(2_Aminoethyl)-1-(6,7,8-difluoro'1g _3_yl)_1,3_dihydroimidon-2-ylthione (R)-5-(2-Aminoethyl)-1-(6-gas oxime oxime_3_yldihydrogen 135964.doc * 15 - 200927740 imidazole-2-thione; (R)- 5-(2-Aminoethyl)-b (6-methoxy-8-azetidin-3-yl)-1,3-dihydromiso-2-thione; (R)-5- (2-Aminoethyl)-1-(6-stone-succinyl-3-yl)-1,3-dihydroimidazole-2-thione; (R)-5-(2-Aminoethyl) - 1- 0 nitroindol-3-yl)-1,3-dihydroimidazole-2-thione; (R)-5-(2-aminoethyl)-1_[6-(ethenyl) Amino) acridine-3-yl]-1,3·dihydroimidazole-2- «thione; (R)-5-aminomethyl-1-acridin-3-yl-1,3-di Hydrogen imidazole-2-thiol ketone; (R)-5-aminomethyl-1-(6-hydroxyindol-3-yl)-1,3-dihydroimidazole-2-disulfide _; (R) _5-(2-Aminoethyl)-1-(6-hydroxy-7-benzyl acridine-3-yl)-1,3-dihydroimidazole·2·thione; (R)-5-amine Methyl-1-(6,8-difluorop-butyl-3-yl)-1,3-dihydroimidazole-2-thione; (R)-5-(3-aminopropyl)- 1-(6,8--fluorop-butyl-3-yl)-1,3-dihydroflavor&lt;» sit-2-thione; (R)-5-(2-pyrylaminoethyl )-1-(6-methoxyacridin-3-yl)-1,3-di-n-imidazole-2-thione; (R)- 5-(2·benzylaminoethyl)·1-(6-hydroxyindole “end-3-yl)-1,3-dihydroflavin-2-thione; (R)-l-(6 -hydroxyindole-3-yl)-5-(2-methylaminoethyl)-1,3-dihydroimidazole-2-thioindole; (R)_i_(6,8-difluoroanthracene- 3-yl)-φ 5_(2_methylaminoethyl)·1,3-dihydroimidon-2-thione or (R)-lp gram spray 3- 3--5-(2-A Aminoethyl)-1,3-dihydroimidon-2-inone. 99. The method of claim 98, wherein the salt is a hydrochloride salt. The method of any one of claims 94 to 95, wherein the compound of formula e is the R or S enantiomer of the compound of formula P. 135964.doc -16- 200927740 101.—種式I化合物,135964.doc -16- 200927740 101. - a compound of formula I, 其中Ri、R2及R3為相同或不同且表示氫、鹵素、烷基、 • 烷基氧基、羥基、硝基、烷基羰基胺基、烷基胺基或二 ,烷基胺基,其中:術語烷基意謂直鏈或支鏈、含有一至 六個碳原子、視情況經芳基、烷氧基、齒素、烷氧羰基 φ 或羥基羰基取代之烴鏈;術語芳基意謂視情況經烷基氧 基、鹵素或硝基取代之苯基或萘基;且術語i素意謂 氟、氣、溴或碘。 102.如請求項101之化合物I,其具有式IAWherein Ri, R2 and R3 are the same or different and represent hydrogen, halogen, alkyl, • alkyloxy, hydroxy, nitro, alkylcarbonylamino, alkylamino or dialkylamino, wherein: The term alkyl means a straight or branched chain hydrocarbon chain containing from one to six carbon atoms, optionally substituted by aryl, alkoxy, dentate, alkoxycarbonyl φ or hydroxycarbonyl; the term aryl means optionally A phenyl or naphthyl group substituted by an alkyloxy group, a halogen or a nitro group; and the term i means means fluorine, gas, bromine or iodine. 102. The compound I of claim 101, which has the formula IA 103.—種式V化合物 ❹103.—Formula V compound ❹ fV、〇' V 104·如請求項103之化合物V,其具有式VAfV, 〇' V 104. The compound V of claim 103, having the formula VA 135964.doc -17- 200927740135964.doc -17- 200927740 106·如請求項105之化合物VI,其具有式VIA106. The compound VI of claim 105, having the formula VIA 107.—種式II化合物107. - Compound of formula II 108.如請求項107之化合物II,其具有式IIA108. The compound II of claim 107, which has the formula IIA 109.如請求項101、103、105或107中任一項之化合物,其中 R!、R2及R&gt;3之至少一者為氟·。 135964.doc 18- 200927740 七、 指定代表圖: (一) 本案指定代表圖為:(無) (二) 本代表圖之元件符號簡單說明: 八、 本案若有化學式時,請揭示最能顯示發明特徵的化學式:The compound according to any one of claims 101, 103, 105 or 107, wherein at least one of R!, R2 and R&gt;3 is fluorine. 135964.doc 18- 200927740 VII. Designated representative map: (1) The representative representative of the case is: (none) (2) The symbol of the symbol of the representative figure is simple: 8. If there is a chemical formula in this case, please reveal the best display invention. Characteristic chemical formula: N 0、N 0, 0 Y r4 B 135964.doc -6-0 Y r4 B 135964.doc -6-
TW097143774A 2007-11-13 2008-11-12 Process TW200927740A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98746707P 2007-11-13 2007-11-13
US8592708P 2008-08-04 2008-08-04

Publications (1)

Publication Number Publication Date
TW200927740A true TW200927740A (en) 2009-07-01

Family

ID=40550012

Family Applications (1)

Application Number Title Priority Date Filing Date
TW097143774A TW200927740A (en) 2007-11-13 2008-11-12 Process

Country Status (13)

Country Link
US (1) US20100298580A1 (en)
EP (1) EP2217585A2 (en)
JP (1) JP2011503175A (en)
KR (1) KR20100102606A (en)
CN (1) CN101952271A (en)
AR (1) AR069311A1 (en)
AU (1) AU2008321625A1 (en)
BR (1) BRPI0818105A2 (en)
CA (1) CA2705512A1 (en)
MX (1) MX2010005193A (en)
RU (1) RU2010123778A (en)
TW (1) TW200927740A (en)
WO (1) WO2009064210A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201316410D0 (en) 2013-09-13 2013-10-30 Bial Portela & Ca Sa Processes for preparing peripherally-selective inhibitors of dopamine-?-hydroxylase and intermediates for use therein
US11875700B2 (en) 2014-05-20 2024-01-16 Jessica Robinson Systems and methods for providing communication services
CN110590728B (en) * 2019-10-15 2022-03-22 青岛科技大学 Synthesis method of polysubstituted 4-phenyl chroman compounds

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0232279B2 (en) * 1982-08-12 1990-07-19 Kowa Co JIHIDOROBENZOPIRANJIOORUNOSEIHO
SE8605504D0 (en) * 1986-12-19 1986-12-19 Astra Laekemedel Ab NOVEL CHROMAN DERIVATIVES
JPH09512269A (en) * 1994-04-26 1997-12-09 シンテックス(ユー・エス・エイ) インコーポレイテッド Benzocycloalkyl azole thione derivative
US6867224B2 (en) * 2002-03-07 2005-03-15 Warner-Lambert Company Compounds that modulate PPAR activity and methods of preparation
JP2004075614A (en) * 2002-08-20 2004-03-11 Sankyo Co Ltd Pharmaceutical containing chromene derivative
US7125904B2 (en) * 2002-10-11 2006-10-24 Portela & C.A., S.A. Peripherally-selective inhibitors of dopamine-β-hydroxylase and method of their preparation
US20050032873A1 (en) * 2003-07-30 2005-02-10 Wyeth 3-Amino chroman and 2-amino tetralin derivatives
US7456214B2 (en) * 2004-05-03 2008-11-25 Baylor University Chromene-containing compounds with anti-tubulin and vascular targeting activity
US20050245489A1 (en) * 2004-05-03 2005-11-03 Pinney Kevin G Chromene-containing compounds with anti-tubulin and vascular targeting activity
UA85597C2 (en) * 2004-06-25 2009-02-10 Янссен Фармацевтика Н.В. Quaternary salt ccr2 antagonists
RU2442781C2 (en) * 2004-10-14 2012-02-20 Абботт ГмбХ унд Ко. КГ Arylsulfonylmethyl or arylsulfonamide derivatives of aromatics, pharmaceutical composition based on them and way of treatment against abnormalities responsive to dopamine d3 receptor ligand treatment, with their help
WO2007067444A1 (en) * 2005-12-08 2007-06-14 Millennium Pharmaceuticals, Inc. Bicyclic compounds with kinase inhibitory activity
PT103901B (en) * 2006-12-12 2012-03-01 Portela & Ca Sa CATALYTIC PROCESS FOR ASYMMETRIC HYDROGENATION.

Also Published As

Publication number Publication date
BRPI0818105A2 (en) 2019-09-24
WO2009064210A2 (en) 2009-05-22
KR20100102606A (en) 2010-09-24
EP2217585A2 (en) 2010-08-18
JP2011503175A (en) 2011-01-27
AR069311A1 (en) 2010-01-13
US20100298580A1 (en) 2010-11-25
RU2010123778A (en) 2011-12-20
WO2009064210A3 (en) 2009-12-30
CN101952271A (en) 2011-01-19
MX2010005193A (en) 2010-06-02
CA2705512A1 (en) 2009-05-22
AU2008321625A1 (en) 2009-05-22

Similar Documents

Publication Publication Date Title
US9556142B2 (en) Process for the preparation of (R,S)-nicotine
KR101263032B1 (en) Process for the preparation of 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino] phenoxy}-n-methylpyridine-2-carboxamide
JP5661773B2 (en) Process for the preparation of indoline derivatives and intermediates thereof
TWI305774B (en)
TW200927740A (en) Process
TWI291959B (en) Process for preparing granisetron
TW201035053A (en) Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one
CN110114346A (en) It is used to prepare R-6- hydroxyl -8- [1- hydroxyl -2- [2- (4- methoxyphenyl) -1,1- dimethyl-ethylamino ethyl] -2H-1, the improved method of 4- benzoxazine -3 (4H) -one hydrochloride
US7141667B2 (en) 3-(4-piperidinyl)-2,3,4,5-tetrahydro-1,3-benzodiazepin-2(1H)-one
JP2004514675A (en) Novel desloratadine salt, synthesis method thereof and pharmaceutical composition
CA2529332A1 (en) Method of preparing cis-8b-methyldecahydro-2a,4a,6a,8a-tetraazacyclopenta[fg]acenaphthylene, cis-decahydro-2a,4a,6a,8a-tetraazacyclopenta[fg]acenaphthylene, cyclene and functionalised cyclenes
JP2001514648A (en) Process for the production of arylsulfonyl chloride
TW201014827A (en) Process for synthesizing substituted isoquinolines
US6774230B2 (en) Methods for the preparation of mirtazapine intermediates
US6326495B2 (en) Process for preparing 8-cyclopentyl-6-ethyl-3-[substituted]-5,8-dihydro-4H-1,2,3a,7,8-pentaaza-as-indacenes and intermediates useful therein
JP2009533481A (en) Novel process for the preparation of 4-hydroxyalkylamino-2-nitro-anisole
EP1380585B1 (en) Pyrazolopyridinone as intermediate
EP0760816A1 (en) Process for preparing benzopyran compounds
KR101421032B1 (en) Method for preparing (2-methyl-1-(3-methylbenzyl)-1H-benzo[d]imidazol-5-yl)(piperidin-1-yl)methanone
TW200837066A (en) Preparation of 4-substituted 2-amino-benzo [4, 5]furo[3, 2-d]pyrimidine derivatives
AU2002247130A1 (en) Method for the preparation of mirtazapine intermediates
CZ20001569A3 (en) Process for preparing 8-cyclopentyl-6-ethyl-3-substituted-5,8-dihydro-4H-1,2,3a,7,8-pentaaza-as-indacenes and intermediates useful therein
NZ626732B2 (en) Process for the preparation of (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic acid esters